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The global incidence of melanoma has dramatically increased during the recent decades,
yet the advancement of primary and adjuvant therapies has not kept a similar pace. The
development of melanoma is often centered on cellular signaling that hyper-activates sur-
vival pathways, while inducing a concomitant blockade to cell death. Aberrations in cell
death signaling not only promote tumor survival and enhanced metastatic potential, but
alsocreateresistancetoanti-tumorstrategies.Chemotherapeuticagentstargetmelanoma
tumorcellsbyinducingaformofcelldeathcalledapoptosis,whichisgovernedbytheBCL -2
familyofproteins.TheBCL -2familyiscomprisedofanti-apoptoticproteins(e.g.,BCL -2,BCL -
xL, and MCL -1) and pro-apoptotic proteins (e.g., BAK, BAX, and BIM), and their coordinated
regulation and function are essential for optimal responses to chemotherapeutics. Here we
will discuss what is currently known about the mechanisms of BCL -2 family function with a
focus on the signaling pathways that maintain melanoma tumor cell survival. Importantly,
we will critically evaluate the literature regarding how chemotherapeutic strategies directly
impact on BCL -2 family function and offer several suggestions for future regimens to target
melanoma and enhance patient survival.
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INTRODUCTION
Skin cancer is one of the leading causes of death worldwide.
Presently in the United States, it is estimated that one in
ﬁve people will develop some form of skin cancer due to a
combination of family history, environment, and genetic fac-
tors (see the American Cancer Society for more information,
http://www.cancer.org/Cancer/SkinCancer-Melanoma/Detailed
Guide/melanoma-skin-cancer-risk-factors). DNA damage caused
by ultraviolet irradiation is thought to be the main environmental
culprit behind the development of this disease. Likewise, genetic
disruptionofgenesnecessaryfortheappropriatebalancesbetween
survival,proliferation,andcelldeatharefrequentlyassociatedwith
the development and persistence of cells that result in skin can-
cer. These cancerous cells may also develop mechanisms to evade
theimmunesystemresultinginunimpededcellproliferation,sur-
vival, and metastases. Malignant melanoma is the deadliest form
of skin cancer, and it arises from the uncontrollable cell division
of the basal layer melanin-producing cells called melanocytes (for
in-depthreview,seeIbrahimandHaluska,2009).Melanomacom-
monly involves the skin, but it can occur at other sites such as
the eyes, ears, and gastrointestinal tract. While melanoma only
accounts for 5% of skin cancers, it is responsible for the major-
ity of skin cancer deaths (Jemal et al., 2009). The prognosis of
melanoma is favorable when limited to the skin and wide excision
iscurative.However,theprognosisof metastaticmelanomaisvery
poor with a 5-year survival rate of less than 20%. Presently, the
most used anti-tumor strategy for stage IV metastatic melanoma
is dacarbazine (DITC), which as a single treatment is not very
effective, and is associated with <20% response rate (Tsao et al.,
2004). Adjuvant and combination treatments are also used; for
example,cisplatin,vinblastine,and DTIC (the regimen is referred
to as “CVD”), in combination with interferon alpha-2α (IFNα)
and interleukin-2 (IL-2),but none have proven to be signiﬁcantly
effective, yet they demonstrate substantial toxicity (Legha et al.,
1989, 1996; Phan et al., 2001). In the majority of cases where a
response does occur,there is often recurrence of the cancer within
months.Abetterunderstandingof thepathwaysthatareactivated
to promote melanoma, and targeted during treatment, will hope-
fullyrevealnoveltherapeuticopportunities.Towardtheendofour
discussion, we will propose that manipulating the BCL-2 family
and the mitochondrial pathway may offer a potential therapeutic
inroad to treatment success.
THE MITOCHONDRIAL PATHWAY OF APOPTOSIS
In response to chemotherapeutics, cells attempt to eliminate the
damage or recover from it by engaging stress response pathways
(e.g.,thep53pathway),butoftenthedamageisoverwhelming,and
thetreatedcellsinduceaformof programmedcelldeathknownas
apoptosis (Green and Evan, 2002). Apoptotic signaling can initi-
ate from outside the cell via plasma membrane receptors (referred
to as the “extrinsic pathway”; e.g., CD95/FAS or tumor necro-
sis factor receptor, TNFR), or through stress that originates from
withinthecell(referredtoasthe“intrinsic”or“mitochondrialpath-
way”; e.g., macromolecular damage; Guicciardi and Gores, 2009;
Chipuk et al., 2010). The extrinsic apoptotic pathway is engaged
whenpro-apoptoticligandssuchasTNFαorCD95L/FASLtrigger
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death receptor signaling which directly leads to the activation
of caspases, which are the cysteine–aspartic proteases responsi-
ble for inducing the apoptotic phenotype (e.g., DNA laddering,
loss of plasma membrane asymmetry, and cellular blebbing; Pop
and Salvesen, 2009). The intrinsic pathway is triggered by intra-
cellular stress signals such as DNA damage, oncogenes, hypoxia,
and growth factor withdrawal (Chipuk et al., 2010). These cellu-
lar stressors transcriptionally and post-transcriptionally regulate
theBcellCLL/lymphoma-2(BCL-2)familyof proteins,whichare
responsibleformitochondrialintegrity,subsequentcaspaseactiva-
tion,andapoptosis.Whilethesetwogeneralpathwaysaredistinct,
there are situations of cross-talk where the extrinsic pathway pro-
motes apoptosis through the intrinsic pathway and vice versa. In
these situations, the BCL-2 family of proteins is also crucial con-
trol points of cellular fate. For the most part, cancer cells utilize
and respond to chemotherapeutic agents by regulating the mito-
chondrialpathwayof apoptosis,soourdiscussionswillbefocused
on these signaling mechanisms (Figure 1).
Once the apoptotic program has been initiated by compromis-
ing the outer mitochondrial membrane (OMM), pro-apoptotic
factors are released from the mitochondrial intermembrane space
(IMS), including cytochrome c (Figure 1; Liu et al., 1996).
Monomericapoptoticproteaseactivatingfactor1(APAF-1)coop-
erateswithcytochromecanddATPtoformtheoligomericcaspase
activationplatformreferredtoasthe“apoptosome”(Lietal.,1997;
Zouetal.,1997).Theapoptosomerecruits,dimerizes,andactivates
pro-caspase-9, which then promotes the downstream function of
pro-caspases-3,-6,and -7 (Figure1). Often,this step in the mito-
chondrial pathway is referred to as “the point of no return,” as
mitochondrial function and ATP generation gradually wane, and
proteolytic cleavage of caspase substrates ensues. Caspase activ-
ity is responsible for the morphological phenotypes of apoptosis,
including DNA laddering, loss of plasma membrane asymmetry,
and phagocytosis (Figure1; Logue and Martin,2008). Regulation
of the mitochondrial pathway of apoptosis plays a crucial role
in the development and treatment of melanoma; and it has been
shownthatdefectsinthispathwaycanresultinresistancetotumor
suppressor pathways and treatments (for an in-depth review, see
Soengas and Lowe, 2003).
THE BCL-2 FAMILY OF PROTEINS
The involvement of mitochondria in apoptosis was ﬁrst suggested
when caspase activity resulted from Xenopus oocyte extract co-
incubation with puriﬁed mitochondria (Newmeyer et al., 1994).
FIGURE 1 |The mitochondrial pathway of apoptosis. Following cellular
stress such as DNA damage, the BCL -2 family of proteins is regulated by
transcriptional (increased or decreased) and post-translational (e.g.,
phosphorylation, cleavage, and relocalization) mechanisms. If the cellular
stress is irreparable, the culmination of pro-apoptotic signaling will lead to
mitochondrial outer membrane permeabilization (MOMP), which allows for
the release of soluble intermembrane space proteins, including cytochrome c.
APAF-1, cytochrome c, and dATP then coordinate to promote APAF-1
oligomerization and recruitment of pro-caspase-9; this complex is referred to
as the “apoptosome.”The apoptosome allows for pro-caspase-9 dimerization
and activation, and the subsequent cleavage and activation of executioner
caspases (caspase-3, -6, and -7).These caspases promote the characteristic
phenotypes of apoptosis, e.g., chromatin condensation, DNA laddering, and
plasma membrane blebbing, by cleaving numerous intracellular substrates.
Within the body, apoptotic cells are rapidly cleared by phagocytosis to ensure
tissue homeostasis.
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Thisactivitywasblockedbytheadditionof BCL-2,suggestingthat
BCL-2 could prevent mitochondrial engagement of the cytosol.
Since then, the BCL-2 family has grown to include almost 20
members that are divided into two functional classes of proteins:
anti-apoptotic and pro-apoptotic (Figure 2). Most cells express a
variety of anti-apoptotic and pro-apoptotic BCL-2 proteins, and
through the regulation of their interactions command survival or
commitmenttoapoptosis(foranin-depthreview,seeChipukand
Green, 2008).
Anti-apoptotic BCL-2 proteins are comprised of four BCL-2
homology domains (BH1-4) and are generally integrated within
the OMM, but may be present in other membranes like the
endoplasmic reticulum (Petros et al., 2004). BCL-2, BCL-xL, and
myeloid cell leukemia 1 (MCL-1) are the major members of the
anti-apoptotic BCL-2 repertoire that function to preserve OMM
integrity by directly binding and inhibiting the pro-apoptotic
BCL-2 proteins (Chen et al., 2005; Willis et al., 2005, 2007;
Figure 2).
The pro-apoptotic BCL-2 members are divided into effectors
(whichalsocontainBH1-4)andtheBH3-onlyproteins(Figure2).
The effector proteins BAK (BCL-2 antagonist killer 1) and BAX
(BCL-2 associated x protein) homo-oligomerize into proteolipid
pores within the OMM and are required to promote MOMP and
cytochromecrelease(Lindstenetal.,2000;Weietal.,2001).How-
ever, these effectors require an activation step, upon which they
oligomerize and gain the capacity to permeabilize membranes
composed of mitochondrial lipids (Kuwana et al., 2002). Acti-
vation of BAK and BAX occurs through interaction with so-called
“direct activators” (see below), or by physico-chemical effects of
detergents,mildheat,orelevatedpH(HsuandYoule,1997;Khaled
FIGURE 2 |The BCL-2 family of proteins.The BCL -2 family of proteins is
divided into anti-apoptotic and pro-apoptotic members.The anti-apoptotic
members include: A1, BCL -2, BCL -w, BCL -xL, and MCL -1, all of which
contain four BCL -2 homology domains (termed BH1-4).The pro-apoptotic
proteins are subdivided into “effector” and “BH3-only” members.The
effector proteins, BAK and BAX, also contain BH1-4; while the BH3-only
proteins contain only one domain, a BH3, that is required for interactions
with anti-apoptotic and effector proteins.The BH3-only proteins include:
BAD, BID, BIK, BIM, BMF , bNIP3, HRK, Noxa, and PUMA.The BH1-3
regions form the conserved “BCL -2 core” structural unit, which includes a
hydrophobic groove that binds to BH3 domains. Many of the BCL -2 family
proteins also contain a transmembrane domain (TM).
et al., 2001; Letai et al., 2002; Pagliari et al., 2005). The BH3-
onlyproteinsacttoregulateboththeanti-apoptoticsandeffectors
(Figures 2 and 3). Two of these, BID (BH3 interacting domain
deathagonist)andBIM(BCL-2interactingmediatorofcelldeath),
aredirectactivatorsofBAKandBAX,actingviatheirBH3domains
to induce oligomerization and the permeabilization function of
BAK and BAX (Wei et al., 2000; Kuwana et al., 2002, 2005; Letai
etal.,2002).TheprocessbywhichBAKandBAXpermeabilizethe
OMMiscommonlyreferredtoas“mitochondrialoutermembrane
permeabilization,”or MOMP.
The activation of BAK and BAX leading to MOMP is com-
plex and incompletely understood. Recent in vitro studies show
that activated BID and BAX bind to one another only in
association with membranes, and this precedes BAX oligomer-
ization, which is followed by membrane permeabilization (Lovell
et al.,2008). The accepted viewpoint is that the expression,stabil-
ity,and activation of the BH3-only proteins and their interactions
withtheanti-apoptoticandeffectorproteinssufﬁcientlylinkspro-
apoptotic signal transduction to MOMP(Chipuk et al., 2010).
Broadlyspeaking,regulationof theBH3-onlyproteinsatthetran-
scriptionalandtranslationallevelsdeterminestheOMMintegrity.
When an apoptotic signal is initiated, the anti-apoptotic BCL-
2 proteins are inhibited by the sensitizer/de-repressor BH3-only
proteins (e.g., BAD, BMF, Hrk, Noxa, and PUMA), which allows
for direct activator-induced BAK and BAX activation to promote
MOMP, and subsequent apoptosis (Figure 3). Non-BCL-2 family
direct activator proteins are also described; several reports sug-
gest a direct activator function for cytosolic p53,MAP-1,andASC
(Tan et al., 2001; Chipuk et al., 2004; Ohtsuka et al., 2004). Fur-
thermore, controversy exists regarding the role of PUMA (p53
upregulated modulator of apoptosis) in mediating BAK and BAX
activation,as conﬂicting results suggest that PUMA is either a de-
repressor/sensitizer or direct activator BH3-only protein (Chipuk
et al., 2005; Kuwana et al., 2005; Kim et al., 2009). Finally, the
steps leading to BAK and BAX activation have been unveiled
through studies that focused on structural consequences of BIM
andBAK/BAXinteractions;thesestructuraldetailsarediscussedin
Figure3(Dewsonetal.,2008,2009;Gavathiotisetal.,2008,2010).
In terms of chemotherapeutic success, pushing a cell to undergo
MOMPissuggestedtoenhanceclinicaloutcomes,andthisishigh-
lighted by the development of small molecule inhibitors to the
anti-apoptotic BCL-2 proteins,which lower the cellular threshold
for MOMP and apoptosis (Letai, 2008). We will discuss these in
greater detail later.
MELANOMA AND THE BCL-2 FAMILY
Melanoma is notorious for chemoresistance, and there continues
to be tremendous research focused on identifying the molecular
mechanisms to explain this phenotype (for an in-depth review,
see Hocker et al., 2008). Unlike many other cancers, melanoma
rarely displays mutations within the tumor suppressor p53 path-
way, which does afford the opportunity to pharmacologically
regulate the p53 pathway through chemotherapy-induced DNA
damage and stress-responses, and we will discuss this throughout
(HockerandTsao,2007).However,mutationsinN-RAS[neurob-
lastoma RAS viral (v-ras) oncogene homolog] and B-RAF (v-raf
murine sarcoma viral oncogene homolog B1) are common events
www.frontiersin.org October 2011 | Volume 1 | Article 34 | 3Anvekar et al. The BCL -2 family and melanoma
FIGURE 3 | Mechanisms of action within the BCL-2 family leading to
MOMP .The upstream involvement of the BCL -2 family in apoptosis can be
divided into two parallel activities: de-repression and sensitization.The
de-repression model begins at cellular status quo with anti-apoptotic BCL -2
proteins binding and sequestering BH3-only direct activators (e.g., BCL -2
binds BIM). In response to stress, a de-repressor BH3-only protein is induced
(e.g., BAD), which can then displace the direct activator and liberate it to
activate BAK and BAX.The sensitization model involves the preemptive
binding and inactivation of anti-apoptotic proteins by sensitizer BH3-only
proteins (e.g., BCL -2 binds BAD).This sensitization prevents the inhibition of
direct activator BH3-only proteins induced following apoptotic stimulation
(e.g., BIM), thus lowering the threshold level of direct activator necessary to
activate the effectors BAK and BAX. Unbound direct activator BH3-only
proteins function in the direct activation of BAK and BAX through a transient
interaction.These interactions lead to conformational changes involving
N-terminal rearrangement, which exposes the BH3 domain of BAK and BAX.
Activated BAK monomers pair symmetrically, and oligomerize as sets of
dimers to permeabilize the outer mitochondrial membrane leading to MOMP .
In contrast, activated BAX monomers pair asymmetrically to oligomerize and
promote MOMP .
in melanoma, which are observed in approximately 20 and 70%
of patients, respectively (Shukla et al., 1989; Davies et al., 2002;
Reifenberger et al.,2004; Edlundh-Rose et al.,2006).Additionally,
the loss of PTEN (phosphatase and tensin homolog) expression,
activationoftheAKT/PI3K(phosphatidylinositol3-kinases)path-
way,and loss of CDKN2A (cyclin-dependent kinase inhibitor 2A)
often synergize with B-RAF mutations leading to the progression
frombenignnevus,primarytumor,tometastaticdisease(Haluska
and Hodi, 1998; Kim, 2010; Figure 4).
Activating mutations in N-RAS and B-RAF lead to positive
inﬂuences on the cell cycle, mainly by promoting mitosis and
preventing cells from engaging their repair and stress machiner-
ies, which leads to increased stress and accumulated mutations.
Studies also suggest that the expression of AKT/PI3K is directly
correlated with melanoma progression; and PTEN expression is
subsequently lost by genetic and epigenetic mechanisms to fur-
ther promote AKT/PI3K survival pathways (Steck et al., 1997;
Tsao et al., 1998, 2000; Zhou et al., 2000; Stahl et al., 2004;
Karbowniczek et al., 2008). Indeed, a recent mouse model of
combined B-RAF V600E and PTEN loss provides in vivo evi-
dence that these two pathways are necessary and sufﬁcient to
promote metastatic melanoma formation (Dankort et al., 2009).
To counteract the proliferative signals generated from the above
circumstances, cells can engage inhibitors to the cell cycle, for
example CDKN2A, which encodes for the proteins p16INK4A
(cyclin-dependent kinase inhibitor 2A) and p14ARF (alternative
reading frame); yet CDKN2A is also mutated, genetically lost, or
epigenetically silenced in a signiﬁcant percentage of melanomas
(Castellano and Parmiani,1999). There are numerous other genes
that are targeted during the transition between primary tumor
and metastasis; more recently, the histone variant macroH2A was
shown to suppress tumor progression of malignant melanoma
(Kapoor et al.,2010). In brief,the sum of these mutations leads to
an aggressive disease that is highly resistant to chemotherapeutics
(Figure 4).
For this discussion, we are focused on understanding how
melanomas with signiﬁcant alterations in N-RAS,B-RAF,and the
other pathways listed above fail to engage apoptosis despite aber-
rations in cellular signaling leading to unregulated proliferation
(Figure 4). How are the cellular safeguards against uncontrolled
proliferationsilencedtopreventapoptosis?Moreimportantly,can
we pharmacologically regulate these aberrant pathways to pro-
duce better responses in the clinic? The answers to both of these
questions point in the direction of the BCL-2 family of proteins.
Here,we suggest that this family of anti- and pro-apoptotic mem-
bers may be what allows for melanoma development, survival,
and chemoresistance, yet it offers a pharmacologically tractable
Achilles’ heel for successful combination/adjuvant therapies to
treat malignant melanoma. In general, there are two approaches
to block apoptosis that is normally engaged following deregu-
lated cellular proliferation: the cell may decrease the expression of
pro-apoptotic BCL-2 proteins (e.g., BAX or BIM); or the cell can
over-express anti-apoptotic BCL-2 proteins (e.g.,BCL-2 or MCL-
1).Ineithercase,theresultingphenotypeisthefailuretopromote
BAK/BAX activation, MOMP, and apoptosis following deregu-
lated cellular proliferation cues or chemotherapeutic treatment.
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FIGURE 4 | Melanoma signaling networks, progression, and
inﬂuences by the BCL-2 family. Melanoma originates from
melanocytes in the skin that acquire a series of changes that
promote the progression from a normal phenotype to a nevus,
primary tumor, and eventual metastatic disease. Epigenetically
silenced, mutated, or deleted genes that promote disease progression are
listed and discussed throughout the text. In brief, common mutations
observed early in melanoma development are in the genes encoding N-RAS
and B-RAF , and these are often complemented by mutations in the
melanocyte regulators such as MITF and BCL -2. Subsequent changes to
PTEN, CDKN2A, and mH2A along with activating mutations of the AKT/PI3K
pathway synergize with early mutations. Subsequently, alterations in
pro-apoptotic sensitivity upstream (e.g., p53) and downstream (e.g., APAF-1)
of the mitochondrial pathway of apoptosis are suggested. In parallel to these
events, the expression and function of the BCL -2 family is altered to establish
marked resistance to pro-apoptotic stimulation: there is increased expression
of anti-apoptotic members, and coordinated downregulation of pro-apoptotic
members.
This ultimately leads to metastatic disease with poor progno-
sis and decreased long-term survival despite chemotherapeutic
intervention.
Returning to the pathways that promote melanoma develop-
mentandchemoresistance,itiswidelyregardedthatB-RAFV600E
is the most commonly observed mutation in patients (Davies
et al., 2002; Pollock and Meltzer, 2002). This gain of function
mutation is a valine to glutamic acid substitution at codon 600,
which results in a hyper-activated kinase and subsequent marked
increases in MAPK/ERK signaling (Wan et al., 2004). Increased
B-RAF V600E activity is demonstrated to promote BIM phos-
phorylation, leading to its proteasome-mediated degradation in
several melanoma models (Cartlidge et al., 2008; Sheridan et al.,
2008; Boisvert-Adamo et al., 2009; Goldstein et al., 2009). The
B-RAFV600Emutationisobservedveryearlyinmelanomadevel-
opment starting at the benign nevus stage. Therefore, reducing
BIM levels and all apoptotic pathways that BIM directly regulates
(e.g., cytokine/growth factor withdrawal) likely leads to marked
resistance to apoptosis (Bouillet et al., 1999). Likewise, since BIM
is a direct activator of BAX and BAK, chemotherapies that uti-
lize a BIM-dependent mechanism will likely not be successful
(Letai et al., 2002; Kuwana et al., 2005; Dai et al., 2008). Multiple
otherpro-apoptoticBCL-2proteinsarealsotargetedbytheB-RAF
V600E mutation. Several studies suggest that excessive signaling
through B-RAF and MAPK promotes BAD (BCL-2 antagonist of
cell death) phosphorylation and inactivation,and decreased BMF
(BCL-2 modifying factor) and PUMA expression, and all these
events lead to abrogated BAK/BAX activation, MOMP, and apop-
tosis (Cartlidge et al.,2008; Sheridan et al.,2008; Boisvert-Adamo
et al., 2009; Goldstein et al., 2009; Keuling et al., 2010; Shao and
Aplin, 2010).
There is also a growing literature connecting RAS and B-
RAF mutations to the induction of autophagy. Autophagy is
a catabolic process which promotes the degradation of cyto-
plasm and organelles; and this plays a key role in tumorigenesis
as it often helps cells cope with stress (for in-depth review,
see Kondo et al., 2005). Activating mutations in RAS and B-
RAF promote autophagy, which can restrict tumor cell growth
(Chen and Karantza-Wadsworth, 2009; Maddodi et al., 2010;
Elgendy et al., 2011). In contrast, some tumor cells display an
addiction to autophagy, which can promote glucose metabo-
lism and mitochondrial function, leading to enhanced tumori-
genesis (Guo et al., 2011; Lock et al., 2011). Interestingly, anti-
apoptotic BCL-2 proteins function at the intersection between
autophagy and apoptosis by directly regulating Beclin-1 activity,a
key protein that is required for the initiation of the formation of
the autophagy machinery. Therefore, integrating the mechanistic
interplay between the pathways that promote melanoma devel-
opment, autophagy, and the cell death machinery is of critical
importance to understanding this disease and potential therapeu-
ticstrategies(Levineetal.,2008;Chipuketal.,2010).Importantly,
theregulationof anti-apoptoticBCL-2proteinsbyBH3-onlypro-
teins and BH3 mimetics (discussed later) impacts not only on
apoptosis, but also autophagy, and subsequent changes to stress
signaling, proteostasis, and metabolism; yet we will focus our
discussion on cellular commitment to apoptosis.
The role of the anti-apoptotic BCL-2 proteins in melanoma is
highlighted by the phenotype of the bcl-2 knockout mouse which
displays dramatic graying of the hair because of diminished fol-
licular melanocyte survival (Yamamura et al., 1996). In support
of this phenotype, microphthalmia associated transcription fac-
tor (MITF), a key transcription factor necessary for melanocyte
development and survival, directly induces bcl-2 promoter activ-
ity (McGill et al., 2002). Elevated levels of BCL-2 and MITF can
promote chemoresistance and are associated with melanoma pro-
gression;furthermore,antisenseagainstBCL-2orMITFpromotes
adecreaseinmelanomacellsurvivalandsensitivitytochemother-
apy (Jansen et al., 1998; Gautschi et al., 2001; McGill et al., 2002).
This leads us to ask why melanocytes are solely addicted to BCL-
2? Perhaps this cell type does not express other anti-apoptotic
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BCL-2 proteins, so small increases in BH3-only protein activity
may promote premature MOMP and apoptosis,whereas this nor-
mallytoleratedlevelofBH3-onlyproteinactivitywouldbeactively
sequestered by BCL-2 to allow for stress resolution. Such a lim-
ited repertoire of anti-apoptotic reserve would not appear to
favor chemoresistance. However, the malignant transformation
and chemoresistance seen in melanomas has also been attributed
to increased levels in A1 (BCL-2 related gene A1), BCL-xL, and
MCL-1, allowing for a rather substantial shift in the apoptotic
threshold(Tangetal.,1998;Leiteretal.,2000;ZhangandRosdahl,
2006; Placzek et al., 2010; Zhuang et al., 2010). The upregulation
of these anti-apoptotic proteins during the transition from nevus
to melanoma may indicate their active role in melanoma progres-
sion (Wong et al., 2008). Several additional transcription factors
suchasETS-1(v-etserythroblastosisvirusE26oncogenehomolog
1), and the chromatin remodeling factor DEK, promote MCL-
1 expression, and may present novel mechanisms (and perhaps
chemotherapeutic strategies) as to the mechanism of melanoma
survivalandchemoresistance(Khodadoustetal.,2009;Dongetal.,
2011).
From both in vitro and in vivo melanoma model systems, sev-
erallinesofevidencesuggestthatBCL-2over-expressioncorrelates
with a malignant phenotype and a higher metastatic potential
(Grover and Wilson, 1996; Takaoka et al., 1997; Xie et al., 1997;
Leiter et al., 2000; Utikal et al., 2002; Zhang and Rosdahl, 2006).
This seems logical, as a cell expressing more anti-apoptotic pro-
teins should resist apoptosis despite cues to die following events
from benign status to malignancy and metastasis. However, there
areconﬂictingresultsintheliteraturethatdescribedecreasedBCL-
2 expression during melanoma progression (Saenz-Santamaria
et al., 1994; Ramsay et al., 1995; Tron et al., 1995; Tang et al.,
1998; Korabiowska et al., 1999; Sviatoha et al., 2002). Similarly,
BCL-2 is described to be constitutively expressed in melanocytes,
nevi, and melanoma, with little change in expression levels (Cer-
roni et al., 1995; Collins and White, 1995; Morales-Ducret et al.,
1995; Plettenberg et al., 1995; Miracco et al., 1998; Selzer et al.,
1998; Loggini et al., 2001; Gradilone et al., 2003). The observa-
tions in both these scenarios can be reconciled if we consider
that a cell may have the opportunity to express alternative anti-
apoptotic BCL-2 members, such as BCL-w, BCL-xL, MCL-1, or
A1. Another possibility is downregulation of the pro-apoptotic
effectors BAK and BAX, which is also associated with tumor pro-
gression and decreased patient survival (Fecker et al., 2006; Tch-
ernevandOrfanos,2007).Thebalancebetweenpro-apoptoticand
anti-apoptoticBCL-2memberscouldalsobeconsideredtocontrol
apoptosis. For example, the BAX/BCL-2 ratio in chemotherapy-
sensitive cells is relatively higher than in cells displaying chemore-
sistance (Raisova et al., 2001). However, great caution should be
employed with monitoring only a few proteins, as MOMP and
apoptosis proceed when multiple BH3-only proteins collaborate
to promote BAK/BAX activation. Understanding the dynamic
and total protein·protein interactions within the BCL-2 family
is more indicative of apoptotic sensitivity and chemotherapeutic
responses. This has been recently applied to tumors of lymphoid
origin,and should be developed to better delineate which patients
have the best chance of chemotherapeutic responses (Deng et al.,
2007; Ryan et al.,2010).
Returning to our original questions, it appears that melanoma
has developed numerous strategies to block apoptosis despite
heightenedcellularproliferationcues:thelossofBH3-onlyprotein
function, along with collateral increases in anti-apoptotic BCL-2
protein expression and diversity. The marked increase in anti-
apoptotic BCL-2 proteins suggests that these cells can engage a
pro-apoptotic response, and that the increased BCL-2 expression
favors a selection process where increased BCL-2 (or other anti-
apoptotic members) confers a survival advantage. Strategies that
promote BH3-only protein function, while also decreasing the
functional anti-apoptotic BCL-2 repertoire, will likely yield the
best clinical responses; indeed, we will discuss the results of such
strategies in the following sections.
MELANOMA TREATMENT AND THE BCL-2 FAMILY
StandardtreatmentsforpatientsdiagnosedwithstageIVmetasta-
tic malignant melanoma are DTIC and IL-2. The FDA approved
DTIC in 1975, and it remains the most commonly used sin-
gle agent chemotherapeutic for metastatic melanoma. DTIC is
an alkylating agent, which prevents DNA replication and sub-
sequently blocks proliferation. Unfortunately, the response rate
is less than 20% and resistance nearly always occurs (Stein and
Brownell, 2008). Other chemotherapeutic agents are currently
being studied to improve late stage melanoma treatment but few
are proving to be more effective than DTIC. For example, temo-
zolomide, a imidazotetrazine-derivative of DTIC, was tested in
clinical trials but did not improve the overall survival of patients
compared to DTIC (Patel et al., 2011). In addition to the stan-
dard combination chemotherapy regimens [e.g., CVD (cisplatin,
vinblastine,DTIC),Dartmouth (DTIC,cisplatin,carmustine,and
tamoxifen), and BOLD (bleomycin, vincristine, lomustine, and
DTIC)], a number of novel adjuvant therapies are currently
being evaluated to improve the efﬁciency of DTIC-based treat-
ments (Seigler et al., 1980; Legha et al., 1989; Lattanzi et al.,
1995).Inparticular,Ipilimumab,ahumanIgG1monoclonalanti-
body that recognizes cytotoxic T-lymphocyte-associated antigen
4 (CTLA-4), enhances T-cell activation, proliferation, and attack
of cancer cells (Melero et al., 2007; O’Day et al., 2007; Fong
and Small, 2008; Robert and Ghiringhelli, 2009; Hodi et al.,
2010). The combination of DTIC and Ipilimumab was recently
shown to be associated with a signiﬁcant increase in survival
among patients with untreated metastatic melanoma (Robert
et al.,2011).
The mechanism of action for DTIC-based therapies is to kill
tumor cells by DNA damage, and these treatments likely signal
through the p53 pathway to induce apoptosis (Igney and Kram-
mer, 2002; Vousden and Lane, 2007). Fortunately, p53 is rarely
targeted in melanoma, so the pro-apoptotic arm of the p53 path-
way has the potential to be engaged. DTIC also directly impacts
on the BCL-2 family from several angles: there is downregula-
tion of anti-apoptotic proteins, and coordinated upregulation of
BH3-only proteins and effector molecules, like BIM and BAX,
respectively (Weber et al., 2009; Jiang et al., 2010b). Importantly,
DTIC has been studied in multiple cellular models of melanoma,
and the consistent observation is that DTIC promotes apopto-
sis through a marked regulation of the BCL-2 family leading to
MOMP.Butwhataccountsforthelowresponserateof melanoma
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patients to DTIC? Can the threshold for BAK/BAX activation,
MOMP, and apoptosis be lowered to increase DTIC responses
in patients? There is minimal information regarding how combi-
nation chemotherapy regimens (e.g., CVD) impact on the BCL-2
family. It is therefore essential to better understand the mech-
anisms of action to design appropriate co-administered adjuvant
therapies.Anon-exhaustivelistofseveralchemotherapeuticdrugs
(some discussed below) and their impact on the BCL-2 family in
common melanoma cell lines is provided in Table 1.
In terms of a targeted therapeutic approach, the frequency of
the B-RAF V600E mutation in melanoma presents a novel and
unique drug target (Davies et al., 2002; Sheridan et al., 2008).
Early studies with B-RAFV600E mutated melanoma lines suggest
that silencing B-RAF V600E expression leads to greater sensi-
tivity to apoptosis, which is likely mediated by the combined
stabilization and function of BIM to promote BAK/BAX activa-
tion (Jiang et al., 2010a). In recent years, treatment of melanoma
patients harboring the B-RAF V600E mutation with small mol-
ecules (e.g., PLX-4720, PLX-4032) that speciﬁcally inhibit the
B-RAF V600E kinase has been successful through Phase III
clinical trials, and appears to offer greater response rates and
increased overall survival compared to DTIC (Flaherty et al.,
2010).
However,melanomacellstreatedwiththesedrugshaveameans
of becoming resistant to declining levels of B-RAF signaling. For
instance, if PTEN expression or function is lost, there are sug-
gestions in the literature that melanoma cell lines can develop
resistance to PLX-4720 induced death due to decreased BIM
(Paraiso et al., 2011). The loss of PTEN results in constitutive
activation of the PI3K/AKT pathway, which has been described
in melanoma suggesting B-RAF inhibitors will only work for a
subset of patients carrying the B-RAF V600E mutation and func-
tional PTEN (VanBrocklin et al., 2009). Dual requirements for
the PI3K/AKT pathway and constitutive MAPK signaling are also
supported by combination treatments such as Sorafenib [small
molecular inhibitor of several tyrosine protein kinases (VEGFR
and PDGFR) and B-RAF] and nanoliposomal ceramide, which
havebeenshowntosynergisticallydecreasePI3K/AKTandMAPK
signaling leading to increased sensitivity to the mitochondrial
pathway of apoptosis in vitro (Tran et al., 2008). Furthermore,
several MEK pathway inhibitors, such as UO126 and CI-1040,
have also been shown to cause upregulation of pro-apoptotic
BCL-2 protein function like BIM, BMF, Noxa, and PUMA, and
occasionally can lead to the downregulation of anti-apoptotic
proteins like BCL-2 and MCL-1 (Wang et al., 2007; VanBrocklin
et al.,2009). Perhaps combinations of B-RAF and MEK inhibitors
can promote more robust apoptosis due to dual regulations of
numerous anti- and pro-apoptotic BCL-2 members (Wang et al.,
2007).
From our discussion, we suggest that melanoma likely devel-
ops because of altered BCL-2 family function, which allows for
survival and proliferation despite signals to die. Likewise, litera-
ture supports that chemotherapies engage apoptosis by directly
promoting the function of pro-apoptotic BCL-2 members. If so,
are there other drugs that can be used in combination with DTIC
to alter the balance toward death, perhaps by decreasing anti-
apoptoticBCL-2proteinexpression,orbyinhibitingtheirfunction
by inducing BH3-only proteins? Indeed, there is already an abun-
dant literature to show that many drugs can directly regulate
the BCL-2 family to favor turning on the mitochondrial path-
way of apoptosis (Table 1). Numerous DNA damaging agents,
such as cisplatin, directly impinge on the mitochondrial pathway
of apoptosis by lowering anti-apoptotic BCL-2 protein expres-
sion, while also increasing effector levels, and presumably, activa-
tion and MOMP (Shibuya et al., 2003). Endoplasmic reticulum
stress induced by tunicamycin or thapsigargin can also induce
apoptosis of melanoma cells, which has been shown to directly
up-regulate PUMA expression (Jiang et al., 2008). Proteasome
inhibitors such as bortezomib have been shown to induce BID,
Noxa, and PUMA in melanoma cells (Nikiforov et al., 2007;
Seeger et al., 2010). Drugs with diverse mechanisms of action
including dihydroartemisinin (promotes oxidative stress), ADI-
PEG20 (arginine deiminase),and aminooxyacetate (transaminase
inhibitor) appear to directly regulate Noxa expression, which has
been shown to directly impact on cellular sensitivity to both
intrinsic and extrinsic forms of apoptosis (Qin et al., 2010; You
et al., 2010; Cabello et al., 2011). The overall outcome of such
studies suggests that the BCL-2 family determines the chemother-
apeutic response to either engage apoptosis or continue with
survival. Indeed, several drugs are suggested to promote apop-
tosis via BIM, which nicely parallels existing clinical data that
shows melanoma progression and poor survival rates are asso-
ciated with decreased BIM expression (Cartlidge et al., 2008; Dai
et al., 2008). Are there strategies to sensitize melanoma cells to
chemotherapeutics by using this information? In the following
section,weprovideevidencethatdepletingcellularanti-apoptotic
BCL-2 function may be the optimal combination therapy to
promotechemotherapeuticresponsesdespiteover-expressedanti-
apoptotic BCL-2 members or decreased pro-apoptotic BCL-2
engagement.
BCL-2 FAMILY INHIBITORS AND MELANOMA TREATMENT
RESPONSES
As mentioned, the BCL-2 family of proteins can inﬂuence both
the progression and chemotherapeutic responses of melanoma.
Whileconventionalchemotherapeuticregimenscanmodulatethe
levels of individual anti- and/or pro-apoptotic BCL-2 proteins,
changes in one or two proteins will likely induce only minor
effects in the pro- and anti-apoptotic balance. Furthermore,since
anti-apoptotic proteins are numerous, there are multiple mem-
bers with the potential to inhibit pro-apoptotic signaling lead-
ing to chemoresistance. While there are notions to suggest that
loss of BID/BIM or BAK/BAX can lead to cancer development
and/or chemoresistance, most data suggest that these proteins
are not commonly targeted, which affords the over-expressed
anti-apoptotic members a unique opportunity for pharmacolog-
ical regulation (Letai, 2008). With this understanding, directly
targeting the anti-apoptotic BCL-2 proteins, and indirectly the
pro-apoptotic machinery they control, is an attractive tool with
potential to generate new therapies, as well as complement exist-
ing treatments. In this endeavor, the greatest successes have come
through the identiﬁcation of small molecules that mimic the
function of BH3-only proteins to bind within the hydropho-
bic pocket of the anti-apoptotic BCL-2 proteins. These small
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Table 1 |A list of chemotherapeutics that induce changes to the BCL-2 family in various melanoma cell lines.
Cellular target Drug BCL-2 family effect Model References
Anti-oxidant/anti-
inﬂammatory?
Vernolide-A BAX Upregulation B16-F10 Pratheeshkumar and Kuttan (2011a)
BCL -2 Downregulation B16-F10 Pratheeshkumar and Kuttan (2011a)
B-RAF PLX-4720 BIM-EL Upregulation Mel-RMu (B-RAFV600E) Jiang et al. (2010a)
BIM-L Upregulation Mel-RMu (B-RAFV600E) Jiang et al. (2010a)
BIM-S Upregulation Mel-RMu (B-RAFV600E) Jiang et al. (2010a)
DNA Fotemustine PUMA Downregulation 1205Lu Weber et al. (2009)
Noxa Upregulation 1205Lu Weber et al. (2009)
Cisplatin BAX Upregulation G361 Shibuya et al. (2003)
BCL -2 Downregulation G361 Shibuya et al. (2003)
Dacarbazine BAX Upregulation A375 Jiang et al. (2010b)
BCL -XL Downregulation FEMIX-1 Lillehammer et al. (2007)
BCL -XL Downregulation A375 Jiang et al. (2010b)
BIM Upregulation 1205Lu Weber et al. (2009)
MCL -1 Downregulation FEMIX-1 Lillehammer et al. (2007)
MCL -1 Downregulation A375 Jiang et al. (2010b)
Noxa Upregulation 451Lu, 1205Lu Weber et al. (2009)
ER stress Thapsigargin BCL -2 Upregulation Mel-RM, MM200 Jiang et al. (2008)
MCL -1 Upregulation Mel-RM, MM200 Jiang et al. (2008)
Noxa Upregulation Mel-RM, MM200 Jiang et al. (2008)
PUMA Upregulation Mel-RM, MM200 Jiang et al. (2008)
Tunicamycin BCL -2 Upregulation Mel-RM, MM200 Jiang et al. (2008)
MCL -1 Upregulation Mel-RM, MM200 Jiang et al. (2008)
Noxa Upregulation Mel-RM, MM200 Jiang et al. (2008)
PUMA Upregulation Mel-RM, MM200 Jiang et al. (2008)
GST Nomilin BAX Upregulation B16-F10 Pratheeshkumar et al. (2011)
BCL -2 Downregulation B16-F10 Pratheeshkumar et al. (2011)
Hydrogen disulﬁde
donor
Diallyl trisulﬁde BCL -2 Downregulation A375, M14 Zhou et al. (2009)
BCL -XL Downregulation A375, M14 Zhou et al. (2009)
MAPK pathway UO126 BAD Upregulation Mel-RM Wang et al. (2007)
BIM-EL Upregulation Mel-RM, MM200 Wang et al. (2007)
BIM-L Upregulation Mel-RM, MM200 Wang et al. (2007)
BIM-S Upregulation Mel-RM, MM200 Wang et al. (2007)
PUMA Upregulation Mel-RM, MM200 Wang et al. (2007)
Multiple targets Phenoxodiol BAD Upregulation IgR3, ME4405 Yu et al. (2006)
BIM Upregulation IgR3, ME4405, MEL -AT, MEL -RM Yu et al. (2006)
Noxa Upregulation ME4405, MEL -AT Yu et al. (2006)
PUMA Upregulation ME4405, MEL -AT Yu et al. (2006)
NF-κB Sulforaphane BAX Upregulation B16-F10 Hamsa et al. (2011)
BCL -2 Downregulation B16-F10 Hamsa et al. (2011)
BID Downregulation B16-F10 Hamsa et al. (2011)
Gambogic acid BAX Upregulation A375 Xu et al. (2009)
BCL -2 Downregulation A375 Xu et al. (2009)
NF-κB and AP-1 Andrographolide BAX Upregulation B16-F10 Pratheeshkumar and Kuttan (2011b)
BCL -2 Downregulation B16-F10 Pratheeshkumar and Kuttan (2011b)
Oxidative stress Dihydroartemisinin Noxa Upregulation A375, G361 Cabello et al. (2011)
PUMA Upregulation A375 Cabello et al. (2011)
Peptidase Elaﬁn BAX Upregulation A2058 Yu et al. (2010)
Noxa Upregulation A2058 Yu et al. (2010)
PUMA Upregulation A2058 Yu et al. (2010)
Proteasome MG-132 MCL -1 Upregulation A375, WM852c Miller et al. (2009)
Noxa Upregulation A375, WM852c Miller et al. (2009)
(Continued)
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Table 1 | Continued
Cellular target Drug BCL-2 family effect Model References
Bortezomib BID Upregulation MeWo Seeger et al. (2010)
MCL -1 Upregulation MeWo Seeger et al. (2010)
Noxa Upregulation MeWo Seeger et al. (2010)
PUMA Upregulation MeWo Seeger et al. (2010)
Transaminase Aminooxyacetate BCL -2 Downregulation C8161, UACC3093 Qin et al. (2010)
MCL -1 Downregulation A375, C8161, UACC3039 Qin et al. (2010)
Noxa Upregulation A375, C8161, UACC3039 Qin et al. (2010)
molecules, referred to as “BH3 mimetics,” functionally neutral-
ize several anti-apoptotic proteins, thus inhibiting their ability to
sequester pro-apoptotic proteins. This strategy lowers the cellular
thresholdleadingtoBAK/BAXactivation,MOMP,andsubsequent
apoptosis.
ThenotionthatregulatingBCL-2functioninmelanomacould
yieldenhancedresponsestochemotherapeuticsarosefromastudy
that showed bcl-2 antisense improved treatment responses and
tumor burden in a xenograft mouse model of human disease
(Jansen et al., 1998). However, the use of bcl-2 antisense adju-
vanttherapy(Oblimersensodium)withdacarbazinefailedtomeet
expectations in several trials (conducted by Genta Incorporated),
although there continues to be some controversy as to whether or
not bcl-2 antisense is beneﬁcial (Jansen et al.,2000;Bedikian et al.,
2006). Independent of those results, pharmacological regulation
of anti-apoptotic BCL-2 proteins continues to be of tremendous
interest. A BH3 mimetic that has been studied with considerable
success in melanoma is the Abbott compound ABT-737 (and the
bio-available form ABT-263). Published in 2005, ABT-737 was
identiﬁed using a structural activity relationship by nuclear mag-
netic resonance (SAR by NRM) screen for compounds that could
bind within the hydrophobic groove of BCL-xL (Oltersdorf et al.,
2005). Upon its discovery, ABT-737 was determined to have high
afﬁnity for the anti-apoptotic BCL-2 proteins BCL-2,BCL-w,and
BCL-xL, but not A1 or MCL-1. ABT-737 was immediately cast as
a promising new drug candidate since it could engage multiple
anti-apoptotic BCL-2 family members,and it demonstrated min-
imal toxicity as a single agent. However, the inability of ABT-737
to inhibit MCL-1 (or A1,however,A1 has restricted expression so
theinﬂuenceincancerisfarlessthanMCL-1),whichiscommonly
over-expressed in melanomas,highlighted one weakness for using
ABT-737 in melanoma, and suggested a possible mechanism by
which ABT-737 resistance may be conferred (Yecies et al., 2010).
Indeed, melanoma survival and sensitivity to chemotherapeutics
appears to be mediated by a combination of anti-apoptotic BCL-
2 members as preclinical studies using antisense oligonucleotides
against BCL-2, BCL-xL, or MCL-1 sensitized to chemotherapy-
induced apoptosis (Gautschi et al., 2001; Del Bufalo et al., 2003;
Thallinger et al.,2003).
To better understand their combined inﬂuence on cellu-
lar survival, a recent study examined the result of reduced
MCL-1 expression in combination with ABT-737 treatment
in melanoma cells (Keuling et al., 2009). Indeed, the results
showed an increased induction of apoptosis, and opened up
the possibility for pro-apoptotic synergy between ABT-737 and
classical chemotherapeutic treatments that decrease MCL-1 lev-
els. Intriguingly, such combination regimens have already yielded
a number of successful studies. For example, ABT-737 in com-
bination with the standard clinically approved anti-melanoma
drug, dacarbazine, promoted apoptosis through the induction of
Noxa, which likely synergizes with ABT-737 to fully inhibit the
anti-apoptotic repertoire (Weber et al., 2009). In a similar sce-
nario,ABT-737synergizedwiththeproteasomeinhibitorMG-132,
which was also suggested to induce Noxa expression and inhibi-
tion of MCL-1 function leading to increased rates of apoptosis
(Fernandez et al., 2005; Qin et al.,2005; Miller et al., 2009). Alter-
natively, because of frequent mutations in the MAPK pathway in
melanoma, ABT-737 has also been studied in combination with
MEK and p38 inhibitors, both of which synergize to enhance the
apoptotic machinery (Cragg et al.,2008; Keuling et al.,2010).
TW-37 is another BH3 mimetic, but it has a broader range of
targets including BCL-2, BCL-xL, and MCL-1(Verhaegen et al.,
2006). Due to the ability of TW-37 to inhibit multiple members,
in particular MCL-1, it was proposed that TW-37 could syner-
gize with chemotherapeutics to promote apoptosis independently
of Noxa regulation. Indeed, when melanoma lines were treated
with TW-37 and a MEK inhibitor (U0126), signiﬁcant apopto-
sis resulted. Interestingly, the observed synergy did not occur in
normalmelanocytes,suggestingthatthemechanismof actionwas
speciﬁc to tumor cells. Curiously,the observed apoptosis was also
dependent upon the p53 pathway, which is functionally intact in
the majority of melanoma cell lines and patients.
Obatoclaxisalsoaninhibitortotheanti-apoptoticBCL-2fam-
ily proteins that has been studied in melanoma. First described in
2007, Obatoclax is believed to inhibit all of the anti-apoptotic
BCL-2 proteins, including MCL-1, and thus shows less resistance
totreatmentthanABT-737(Nguyenetal.,2007).WhileObatoclax
has been shown to induce apoptosis as a single agent treatment
in other types of cancer, such efﬁcacy has not been observed
in melanoma, leading to the study of combination treatments
(Trudel et al.,2007).When combined with the endoplasmic retic-
ulum stressors tunicamycin or thapsigargin, increased apoptosis
wasobserved(Jiangetal.,2009).ThissynergyislikelyduetoOba-
toclaxfunctioninglikeasensitizerBH3-onlyproteintoinhibitthe
anti-apoptotic BCL-2 proteins,lowering the cellular threshold for
BAK/BAX activation, and allowing the mitochondrial apoptotic
machinery to be engaged when signaled. However, it should be
noted that despite its conﬁrmed inhibiting interaction with the
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anti-apoptotic BCL-2 proteins, albeit at a higher concentrations
than ABT-737, the mechanism by which obatoclax elicits a
response is not deﬁnitive, as studies have suggested alternative
targets than the BCL-2 family (Konopleva et al.,2008).
While the above drugs target the anti-apoptotic BCL-2 pro-
teins, none of them have proven to be as effective at binding
the anti-apoptotics proteins as the BH3-only proteins themselves.
Given the importance of the BH3 domain – anti-apoptotic inter-
action, which lowers the cellular threshold of apoptosis, short
chemically synthesized peptides mimicking the different BH3-
only proteins have been generated and tested for function (Letai
et al., 2002). Indeed, BH3 domain peptides from different BH3-
onlyproteinsrevealedthedistinctionbetweendirectactivatorand
sensitizer/de-repressor BH3-only proteins (Figure 3). The BID
and BIM BH3 domain peptides promote BAK/BAX-dependent
MOMPandcytochromecrelease,whereastheBADBH3promotes
MOMP by inhibiting BCL-2, BCL-xL, and BCL-w (and revealing
BID/BIMactivity,seeFigure3),andnotbydirectBAK/BAXinter-
actions (Chen et al., 2005; Kuwana et al., 2005). One issue that
arose with using synthetic peptides was the loss of α-helicity that
isrequiredforprotein-proteininteractionsbetweentheBH3-only
proteinsandtheanti-apoptotics.Toaddressthisissue,non-natural
amino acids containing oleﬁn-bearing tethers were introduced
into the BH3 domain sequence, effectively “stapling” the peptide
into an α-helical form (Walensky et al., 2004, 2006). These sta-
pled BH3 domains are referred to as “stabilized α-helix of BCL-2
domains”(SAHBs), and these may serve as a new tool for design-
ing cancer therapeutics to target the BCL-2 family and enhance
endogenous BH3-only activity. For example, the BID BH3 SAHB
was shown to induce apoptosis in leukemia cells as well as inhibit
growth of human leukemia xenografts in vivo (Walensky et al.,
2004).Recently,aMCL-1BH3SAHBwasdevelopedwhichinhibits
MCL-1 with very high afﬁnity,and indeed has also been shown to
sensitizecancercellstoapoptosis(n.b.,theMCL-1SAHBuniquely
binds to the MCL-1 hydrophobic groove; Stewart et al., 2010).
The identiﬁcation of an exclusive and potent MCL-1 inhibitor is
important, given the lack of potent inhibitors that target MCL-
1 and the emergence of MCL-1 as a chemoresistance factor in a
broadrangeof humancancers.Thesedevelopmentswillhopefully
serve as an additional platform to discover small molecule regula-
torsof theBCL-2family.Presently,BH3domainpeptideshavenot
been examined in the context of melanoma treatment; efforts to
elucidate their potential impact would be useful for understand-
ing both the biology of melanoma, and hopefully its treatment.
Of note,BH3 mimetics also promote autophagy,alone or in com-
bination with B-RAF inhibition; and this may be a contributing
mechanism with therapeutic potential in metastatic melanoma
(Armstrong et al.,2011; Malik et al.,2011a,b).
PERSPECTIVES
Throughout our discussions, we focused on applying the mech-
anisms of action for the BCL-2 family to the regulation of
melanoma tumorigenesis, apoptosis, and treatment. As the BCL-
2 family deﬁnes the balance between life and death in normal
and cancer cells, it is reasonable to seek a full understanding of
the cellular mechanisms that control BCL-2 family function to
establish how stressed cells undergo apoptosis, and how cancer
cells resist pro-apoptotic signals to ensure survival. Here we sug-
gest that multiple anti-apoptotic BCL-2 proteins ensure survival,
andthatmelanocytesundergoingstressduringtumorigenesisand
metastasis increase the expression and/or function of these pro-
survivalmembers.Likewise,chemotherapeutics(singleagentsand
combinations) must promote the inhibition of these pro-survival
members by a combination of BH3-only protein functions to
engageBAK/BAXactivationandachievedesiredclinicaloutcomes.
While we have focused on the direct targeting of the BCL-
2 family to promote MOMP, it is important to mention that
there are also pharmacological opportunities to promote apopto-
sisbothupstreamanddownstreamof mitochondria.Inparticular,
the development of XIAP (X-linked inhibitor of apoptosis pro-
tein) inhibitors is critical as the increased expression of XIAP is
positively correlated with melanoma thickness, tumor progres-
sion, and chemoresistance (Chawla-Sarkar et al., 2004; Kluger
et al., 2007; Emanuel et al., 2008; Hiscutt et al., 2010). XIAP
is a potent inhibitor to the apoptotic caspases, so relieving this
apoptotic brake is predicted to lower the threshold leading to
the cell death phenotype (Eckelman et al., 2006). Indeed, the
development of SMAC (second mitochondria-derived activator
of caspases, the cellular XIAP inhibitor) mimetics to target XIAP
is shown to induce apoptosis in numerous melanoma cell lines
(Vucic et al., 2002; Zobel et al., 2006). There are also numerous
additional pathways that offer opportunities to enhance tumor
cell killing though MOMP and apoptosis. For example,epigenetic
mechanisms are implicated in melanoma survival as miR-149 and
miR-193b enhance Mcl-1 expression in nevi, patient tumor sam-
ples, and melanoma cell lines (Chen et al., 2011; Jin et al., 2011).
Histone deacetylase (HDAC) inhibitors sensitize melanoma cells
to chemotherapy through a number of mechanisms, including
suppression of the RAS/MAPK signaling pathway and enhanced
DNA damage signaling leading to apoptosis (Peltonen et al.,2005;
Kobayashi et al.,2006; Munshi et al.,2006). Furthermore,the role
ofchromatinmodiﬁcationsmayoffercollateralmeansofpharma-
cological intervention as the requirement for SWI/SNF complexes
in MITF regulated melanocyte-speciﬁc gene expression pathways
directly impact on BCL-2 expression, and likely sensitivity to
chemotherapeutics (de la Serna et al., 2006; Keenen et al., 2010;
Vachtenheim et al.,2010). Determining the appropriate combina-
tiontreatmentsforeachpatientbasedonhis/herindividualtumor
status will likely generate the most effective treatments.
Fortunately, the cellular signaling pathways that intersect
betweenthesurvivalandapoptosiscascadesarenumerous(e.g.,B-
RAF mutation and BCL-2 over-expression; proteasome function
and MCL-1 over-expression) and this affords the pharmacolog-
ical opportunity to explore multiple combination strategies to
cure melanoma. In the future,enhanced animal models of human
disease will likely shed light upon the mechanisms that drive
melanocyte tumorigenesis and metastasis. The combined B-RAF
V600E/PTENmousemodelmentionedearlierisperhapstheideal
model system to genetically evaluate the role of the BCL-2 fam-
ily in melanoma progression (Dankort et al., 2009). As further
models are developed, they should be evaluated along side the
standard models of BCL-2 family function (e.g., bak−/− bax−/−,
bid−/−bim−/−, puma−/−, melanocyte-speciﬁc bcl-2 and mcl-1
transgenics, etc...) to fully appreciate the inﬂuence of the BCL-2
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family in mediating melanoma development and treatment. Like-
wise, a better understanding of the pathways (e.g., mitochondrial
dynamics, structural studies, lipid environment etc...) that reg-
ulate the BCL-2 family itself will certainly yield novel target
strategiestoobtainbetterclinicaloutcomes.Thefutureshowssig-
niﬁcant promise to develop more speciﬁc and bio-available small
moleculeinhibitorstotheanti-apoptoticBCL-2proteins,andper-
hapsdrugsthatdirectlypromoteBAK/BAXactivation;thiswillbe
another signiﬁcant milestone in adjuvant-based chemotherapeu-
tic strategies targeting the mitochondrial pathway of apoptosis.
The hope is that as we further dissect the mechanisms of the
BCL-2 family and apoptotic pathways, novel therapeutic targets
and combination strategies will emerge and provide signiﬁcant
beneﬁts to those afﬂicted with melanoma.
ACKNOWLEDGMENTS
WewouldliketothankmembersoftheChipukLaboratoryforuse-
ful discussions and feedback on this review; and the Department
of Dermatology at MSSM for its continued support,especially Dr.
Mark G. Lebwohl. Dr. Christopher W. Akey (Boston University)
for the apoptosome image. We apologize for not discussing and
citingalltherelevantliteratureduetospacerestrictions.Thelabo-
ratoryisfundedbyNIHR01CA157740andissupportedinpartby
Research Grant 5-FY11-74 from the March of Dimes Foundation.
REFERENCES
Armstrong, J. L., Corazzari, M., Mar-
tin,S.,Pagliarini,V.,Falasca,L.,Hill,
D. S., Ellis, N., Al Sabah, S., Red-
fern, C. P., Fimia, G. M., Piacentini,
M., and Lovat, P. E. (2011). Onco-
genic B-RAF signaling in melanoma
impairsthetherapeuticadvantageof
autophagy inhibition. Clin. Cancer
Res. 17, 2216–2226.
Bedikian, A. Y., Millward, M., Peham-
berger, H., Conry, R., Gore, M.,
Trefzer, U., Pavlick, A. C., DeConti,
R., Hersh, E. M., Hersey, P., Kirk-
wood, J. M., Haluska, F. G., and
Oblimersen Melanoma Study
Group. (2006). Bcl-2 antisense
(oblimersen sodium) plus dacar-
bazine in patients with advanced
melanoma: the Oblimersen
Melanoma Study Group. J. Clin.
Oncol. 24, 4738–4745.
Boisvert-Adamo, K., Longmate, W.,
Abel, E. V., and Aplin, A. E. (2009).
Mcl-1 is required for melanoma cell
resistance to anoikis. Mol. Cancer
Res. 7, 549–556.
Bouillet, P., Metcalf, D., Huang, D.
C., Tarlinton, D. M., Kay, T. W.,
Kontgen, F., Adams, J. M., and
Strasser, A. (1999). Proapoptotic
Bcl-2 relative Bim required for
certain apoptotic responses, leuko-
cyte homeostasis, and to pre-
clude autoimmunity. Science 286,
1735–1738.
Cabello, C. M., Lamore, S. D., Bair,
W. B. III, Qiao, S., Azimian, S.,
Lesson, J. L., and Wondrak, G.
T. (2011). The redox antimalarial
dihydroartemisinin targets human
metastatic melanoma cells but not
primary melanocytes with induc-
tionof NOXA-dependentapoptosis.
Invest. New Drugs 1–13.
Cartlidge,R.A.,Thomas,G. R.,Cagnol,
S., Jong, K. A., Molton, S. A.,
Finch, A. J., and McMahon, M.
(2008). Oncogenic BRAF(V600E)
inhibits BIM expression to promote
melanomacellsurvival.PigmentCell
Melanoma Res. 21, 534–544.
Castellano,M.,andParmiani,G.(1999).
Genes involved in melanoma: an
overview of INK4a and other loci.
Melanoma Res. 9, 421–432.
Cerroni, L., Soyer, H. P., and Kerl, H.
(1995). bcl-2 protein expression in
cutaneousmalignantmelanomaand
benignmelanocyticnevi.A m.J.Der-
matopathol. 17, 7–11.
Chawla-Sarkar, M., Bae, S. I., Reu,
F. J., Jacobs, B. S., Lindner, D. J.,
and Borden, E. C. (2004). Down-
regulation of Bcl-2, FLIP or IAPs
(XIAP and survivin) by siRNAs
sensitizes resistant melanoma
cells to Apo2L/TRAIL-induced
apoptosis. Cell Death Differ. 11,
915–923.
Chen, J., Zhang, X., Lentz, C., Abi-
Daoud, M., Pare, G. C., Yang, X.,
Feilotter, H. E., and Tron, V. A.
(2011). miR-193b regulates Mcl-1
in melanoma. Am. J. Pathol. PMID:
21893020. [Epub ahead of print].
Chen, L., Willis, S. N., Wei, A., Smith,
B. J., Fletcher, J. I., Hinds, M.
G., Colman, P. M., Day, C. L.,
Adams, J. M., and Huang, D. C.
(2005).Differentialtargetingof pro-
survivalBcl-2proteinsbytheirBH3-
only ligands allows complementary
apoptotic function. Mol. Cell 17,
393–403.
Chen, N., and Karantza-Wadsworth,
V. (2009). Role and regulation of
autophagy in cancer. Biochim. Bio-
phys. Acta 1793, 1516–1523.
Chipuk, J. E., Bouchier-Hayes, L.,
Kuwana, T., Newmeyer, D. D., and
Green, D. R. (2005). PUMA cou-
ples the nuclear and cytoplasmic
proapoptotic function of p53. Sci-
ence 309, 1732–1735.
Chipuk, J. E., and Green, D. R. (2008).
How do BCL-2 proteins induce
mitochondrialoutermembraneper-
meabilization? Trends Cell Biol. 18,
157–164.
Chipuk, J. E., Kuwana, T., Bouchier-
Hayes, L., Droin, N. M., Newmeyer,
D. D., Schuler, M., and Green,
D. R. (2004). Direct activation
of Bax by p53 mediates mito-
chondrial membrane permeabiliza-
tion and apoptosis. Science 303,
1010–1014.
Chipuk, J. E., Moldoveanu, T., Llambi,
F., Parsons, M. J., and Green, D. R.
(2010). The BCL-2 family reunion.
Mol. Cell 37, 299–310.
Collins, K. A., and White, W. L. (1995).
Intercellular adhesion molecule 1
(ICAM-1) and bcl-2 are differen-
tially expressed in early evolving
malignant melanoma. A m .J .D e r -
matopathol. 17, 429–438.
Cragg, M. S., Jansen, E. S., Cook, M.,
Harris, C., Strasser, A., and Scott,
C. L. (2008). Treatment of B-RAF
mutant human tumor cells with a
MEK inhibitor requires Bim and is
enhanced by a BH3 mimetic. J. Clin.
Invest. 118, 3651–3659.
Dai, D. L., Wang, Y., Liu, M., Martinka,
M., and Li, G. (2008). Bim expres-
sion is reduced in human cutaneous
melanomas. J. Invest. Dermatol. 128,
403–407.
Dankort, D., Curley, D. P., Cartlidge,
R. A., Nelson, B., Karnezis, A. N.,
Damsky, W. E. Jr., You, M. J.,
DePinho, R. A., McMahon, M., and
Bosenberg,M. (2009). Braf (V600E)
cooperates with Pten loss to induce
metastatic melanoma. Nat. Genet.
41, 544–552.
Davies, H., Bignell, G. R., Cox, C.,
Stephens, P., Edkins, S., Clegg, S.,
Teague, J., Woffendin, H., Garnett,
M. J., Bottomley, W., Davis, N.,
Dicks, E., Ewing, R., Floyd, Y., Gray,
K., Hall, S., Hawes, R., Hughes, J.,
Kosmidou, V., Menzies, A., Mould,
C., Parker, A., Stevens, C., Watt, S.,
Hooper,S.,Wilson,R.,Jayatilake,H.,
Gusterson, B. A., Cooper, C., Ship-
ley,J.,Hargrave,D.,Pritchard-Jones,
K., Maitland, N., Chenevix-Trench,
G., Riggins, G. J., Bigner, D. D.,
Palmieri,G.,Cossu,A.,Flanagan,A.,
Nicholson, A., Ho, J. W., Leung, S.
Y., Yuen, S. T., Weber, B. L., Seigler,
H. F., Darrow, T. L., Paterson, H.,
Marais, R., Marshall, C. J., Wooster,
R., Stratton, M. R., and Futreal, P.
A. (2002). Mutations of the BRAF
gene in human cancer. Nature 417,
949–954.
delaSerna,I.L.,Ohkawa,Y.,Higashi,C.,
Dutta, C., Osias, J., Kommajosyula,
N., Tachibana, T., and Imbalzano,
A. N. (2006). The microphthalmia-
associated transcription factor
requires SWI/SNF enzymes to
activate melanocyte-speciﬁc genes.
J. Biol. Chem. 281, 20233–20241.
DelBufalo,D.,Trisciuoglio,D.,Scarsella,
M., Zangemeister-Wittke, U., and
Zupi, G. (2003). Treatment of
melanoma cells with a bcl-2/bcl-
xLantisenseoligonucleotideinduces
antiangiogenic activity. Oncogene
22, 8441–8447.
Deng, J., Carlson, N., Takeyama, K.,
Dal Cin, P., Shipp, M., and Letai,
A. (2007). BH3 proﬁling identiﬁes
three distinct classes of apoptotic
blocks to predict response to ABT-
737 and conventional chemother-
apeutic agents. Cancer Cell 12,
171–185.
Dewson, G., Kratina, T., Czabotar, P.,
Day, C. L., Adams, J. M., and Kluck,
R. M. (2009). Bak activation for
apoptosis involves oligomerization
of dimers via their alpha6 helices.
Mol. Cell 36, 696–703.
Dewson, G., Kratina, T., Sim, H. W.,
Puthalakath, H., Adams, J. M., Col-
man,P. M.,and Kluck,R. M. (2008).
To trigger apoptosis, Bak exposes
itsBH3domainandhomodimerizes
via BH3: groove interactions. Mol.
Cell 30, 369–380.
Dong, L., Jiang, C. C., Thorne, R. F.,
Croft, A., Yang, F., Liu, H., de Bock,
C. E., Hersey, P., and Zhang, X. D.
(2011). Ets-1 mediates upregulation
of Mcl-1 downstream of XBP-1 in
human melanoma cells upon ER
stress. Oncogene 30, 3716–3726.
Eckelman, B. P., Salvesen, G. S., and
Scott, F. L. (2006). Human inhibitor
of apoptosis proteins: why XIAP is
the black sheep of the family. EMBO
Rep. 7, 988–994.
www.frontiersin.org October 2011 | Volume 1 | Article 34 | 11Anvekar et al. The BCL -2 family and melanoma
Edlundh-Rose, E., Egyhazi, S., Omholt,
K., Mansson-Brahme, E., Platz, A.,
Hansson, J., and Lundeberg, J.
(2006). NRAS and BRAF mutations
in melanoma tumours in relation
to clinical characteristics: a study
based on mutation screening by
pyrosequencing. Melanoma Res. 16,
471–478.
Elgendy,M.,Sheridan,C.,Brumatti,G.,
and Martin, S. J. (2011). Oncogenic
Ras-inducedexpressionof Noxaand
Beclin-1 promotes autophagic cell
deathandlimitsclonogenicsurvival.
Mol. Cell 42, 23–35.
Emanuel, P. O., Phelps, R. G., Mudgil,
A., Shaﬁr, M., and Burstein, D.
E. (2008). Immunohistochemical
detection of XIAP in melanoma. J.
Cutan. Pathol. 35, 292–297.
Fecker, L. F., Geilen, C. C., Tch-
ernev, G., Trefzer, U., Assaf, C.,
Kurbanov, B. M., Schwarz, C.,
Daniel, P. T., and Eberle, J. (2006).
Loss of proapoptotic Bcl-2-related
multidomain proteins in primary
melanomas is associated with poor
prognosis. J. Invest. Dermatol. 126,
1366–1371.
Fernandez, Y., Verhaegen, M., Miller, T.
P., Rush, J. L., Steiner, P., Opipari,
A. W. Jr., Lowe, S. W., and Soen-
gas,M.S.(2005).Differentialregula-
tion of noxa in normal melanocytes
and melanoma cells by proteasome
inhibition:therapeuticimplications.
Cancer Res. 65, 6294–6304.
Flaherty, K. T., Puzanov, I., Kim, K.
B., Ribas, A., McArthur, G. A., Sos-
man, J. A., O’Dwyer, P. J., Lee, R. J.,
Grippo, J. F., Nolop, K., and Chap-
man, P. B. (2010). Inhibition of
mutated,activatedBRAFinmetasta-
tic melanoma. N .E n g l .J .M e d .363,
809–819.
Fong, L., and Small, E. J. (2008). Anti-
cytotoxic T-lymphocyte antigen-4
antibody: the ﬁrst in an emerging
class of immunomodulatory anti-
bodies for cancer treatment. J. Clin.
Oncol. 26, 5275–5283.
Gautschi, O., Tschopp, S., Olie, R. A.,
Leech, S. H., Simoes-Wust, A. P.,
Ziegler, A., Baumann, B., Oder-
matt, B., Hall, J., Stahel, R. A.,
andZangemeister-Wittke,U.(2001).
Activity of a novel bcl-2/bcl-xL-
bispeciﬁc antisense oligonucleotide
against tumors of diverse histologic
origins. J. Natl. Cancer Inst. 93,
463–471.
Gavathiotis, E., Reyna, D. E., Davis, M.
L., Bird, G. H., and Walensky, L.
D. (2010). BH3-triggered structural
reorganization drives the activation
of proapoptotic BAX. Mol. Cell 40,
481–492.
Gavathiotis, E., Suzuki, M., Davis, M.
L., Pitter, K., Bird, G. H., Katz, S.
G., Tu, H. C., Kim, H., Cheng, E.
H., Tjandra, N., and Walensky, L. D.
(2008).BAXactivationisinitiatedat
a novel interaction site. Nature 455,
1076–1081.
Goldstein, N. B., Johannes, W. U.,
Gadeliya, A. V., Green, M. R., Fujita,
M., Norris, D. A., and Shellman, Y.
G. (2009). Active N-Ras and B-Raf
inhibit anoikis by downregulating
Bim expression in melanocytic cells.
J. Invest. Dermatol. 129, 432–437.
Gradilone,A.,Gazzaniga,P.,Ribuffo,D.,
Scarpa, S., Cigna, E., Vasaturo, F.,
Bottoni, U., Innocenzi, D., Calvieri,
S.,Scuderi,N.,Frati,L.,andAglianò,
A. M. (2003). Survivin, bcl-2, bax,
and bcl-X gene expression in sen-
tinel lymph nodes from melanoma
patients. J. Clin. Oncol. 21, 306–312.
Green, D. R., and Evan, G. I. (2002). A
matter of life and death. Cancer Cell
1, 19–30.
Grover, R., and Wilson, G. D. (1996).
Bcl-2 expression in malignant
melanoma and its prognostic sig-
niﬁcance. Eur. J. Surg. Oncol. 22,
347–349.
Guicciardi, M. E., and Gores, G. J.
(2009). Life and death by death
receptors. FASEB J. 23, 1625–1637.
Guo, J. Y., Chen, H. Y., Mathew, R.,
Fan, J., Strohecker, A. M., Karsli-
Uzunbas, G., Kamphorst, J. J., Chen,
G., Lemons, J. M., Karantza, V.,
Coller, H. A., Dipaola, R. S., Geli-
nas, C., Rabinowitz, J. D., and
White, E. (2011). Activated Ras
requires autophagy to maintain
oxidativemetabolismandtumorige-
nesis. Genes Dev. 25, 460–470.
Haluska, F. G., and Hodi, F. S. (1998).
Molecular genetics of familial cuta-
neous melanoma. J. Clin. Oncol. 16,
670–682.
Hamsa, T. P., Thejass, P., and Kuttan,
G. (2011). Induction of apoptosis
by sulforaphane in highly metasta-
tic B16F-10 melanoma cells. Drug
Chem. Toxicol. 34, 332–340.
Hiscutt,E.L.,Hill,D.S.,Martin,S.,Kerr,
R., Harbottle, A., Birch-Machin, M.,
Redfern, C. P., Fulda, S., Armstrong,
J. L., and Lovat, P. E. (2010). Tar-
geting X-linked inhibitor of apop-
tosis protein to increase the efﬁcacy
of endoplasmic reticulum stress-
induced apoptosis for melanoma
therapy. J. Invest. Dermatol. 130,
2250–2258.
Hocker, T., and Tsao, H. (2007). Ultra-
violet radiation and melanoma: a
systematic review and analysis of
reported sequence variants. Hum.
Mutat. 28, 578–588.
Hocker, T. L., Singh, M. K., and Tsao,
H. (2008). Melanoma genetics and
therapeutic approaches in the 21st
century:movingfromthebenchside
to the bedside. J. Invest. Dermatol.
128, 2575–2595.
Hodi, F. S., O’Day, S. J., McDermott,
D. F., Weber, R. W., Sosman, J. A.,
Haanen, J. B., Gonzalez, R., Robert,
C., Schadendorf, D., Hassel, J. C.,
Akerley,W., van den Eertwegh,A. J.,
Lutzky, J., Lorigan, P., Vaubel, J. M.,
Linette,G.P.,Hogg,D.,Ottensmeier,
C. H., Lebbé, C., Peschel, C., Quirt,
I., Clark, J. I.,Wolchok, J. D.,Weber,
J. S., Tian, J., Yellin, M. J., Nichol,
G. M., Hoos, A., and Urba, W. J.
(2010). Improved survival with ipil-
imumab in patients with metasta-
tic melanoma. N .E n g l .J .M e d .363,
711–723.
Hsu, Y. T., and Youle, R. J. (1997).
Nonionic detergents induce dimer-
ization among members of the
Bcl-2 family. J. Biol. Chem. 272,
13829–13834.
Ibrahim, N., and Haluska, F. G.
(2009). Molecular pathogenesis of
cutaneous melanocytic neoplasms.
Annu. Rev. Pathol. 4, 551–579.
Igney,F.H.,andKrammer,P.H.(2002).
Death and anti-death: tumour resis-
tance to apoptosis. Nat. Rev. Cancer
2, 277–288.
Jansen, B., Schlagbauer-Wadl, H.,
Brown, B. D., Bryan, R. N., van
Elsas, A., Muller, M., Wolff, K.,
Eichler, H. G., and Pehamberger,
H. (1998). bcl-2 antisense therapy
chemosensitizes human melanoma
in SCID mice. Nat. Med. 4,232–234.
Jansen, B., Wacheck, V., Heere-Ress, E.,
Schlagbauer-Wadl, H., Hoeller, C.,
Lucas, T., Hoermann, M., Hollen-
stein, U., Wolff, K., and Peham-
berger, H. (2000). Chemosensiti-
sation of malignant melanoma by
BCL2 antisense therapy. Lancet 356,
1728–1733.
Jemal, A., Siegel, R., Ward, E., Hao, Y.,
Xu, J., and Thun, M. J. (2009). Can-
cerstatistics,2009.CACancerJ.Clin.
59, 225–249.
Jiang, C. C., Lai, F., Tay, K. H., Croft,
A., Rizos, H., Becker, T. M.,Yang, F.,
Liu,H.,Thorne,R. F.,Hersey,P.,and
Zhang, X. D. (2010a). Apoptosis of
human melanoma cells induced by
inhibition of B-RAFV600E involves
preferential splicing of bimS. Cell
Death Dis. 1, e69.
Jiang, G., Liu, Y. Q., Wei, Z. P., Pei,
D. S., Mao, L. J., and Zheng, J.
N. (2010b). Enhanced anti-tumor
activity by the combination of a
conditionally replicating adenovirus
mediated interleukin-24 and dacar-
bazine against melanoma cells via
induction of apoptosis. Cancer Lett.
294, 220–228.
Jiang, C. C., Lucas, K., Avery-Kiejda,
K. A., Wade, M., deBock, C. E.,
Thorne,R.F.,Allen,J.,Hersey,P.,and
Zhang, X. D. (2008). Up-regulation
of Mcl-1 is critical for survival of
human melanoma cells upon endo-
plasmicreticulumstress.CancerRes.
68, 6708–6717.
Jiang, C. C., Wroblewski, D., Yang, F.,
Hersey, P., and Zhang, X. D. (2009).
Humanmelanomacellsunderendo-
plasmic reticulum stress are more
susceptible to apoptosis induced by
theBH3mimeticobatoclax.Neopla-
sia 11, 945–955.
Jin, L., Hu, W. L., Jiang, C. C., Wang,
J. X., Han, C. C., Chu, P., Zhang,
L. J., Thorne, R. F., Wilmott, J.,
Scolyer, R. A., Hersey, P., Zhang, X.
D., and Wu, M. (2011). MicroRNA-
149*, a p53-responsive microRNA,
functions as an oncogenic regula-
tor in human melanoma. Proc. Natl.
Acad. Sci. U.S.A. 108, 15840–15845.
Kapoor, A., Goldberg, M. S., Cumber-
land, L. K., Ratnakumar, K., Segura,
M. F., Emanuel, P. O., Menendez,
S., Vardabasso, C., Leroy, G., Vidal,
C. I., Polsky, D., Osman, I., Gar-
cia, B. A., Hernando, E., and Bern-
stein, E. (2010). The histone variant
macroH2A suppresses melanoma
progression through regulation of
CDK8. Nature 468, 1105–1109.
Karbowniczek, M., Spittle, C. S., Mor-
rison, T., Wu, H., and Henske,
E. P. (2008). mTOR is acti-
vated in the majority of malignant
melanomas. J. Invest. Dermatol. 128,
980–987.
Keenen, B., Qi, H., Saladi, S. V., Yeung,
M., and de la Serna, I. L. (2010).
HeterogeneousSWI/SNFchromatin
remodeling complexes promote
expression of microphthalmia-
associated transcription factor
target genes in melanoma. Oncogene
29, 81–92.
Keuling, A. M., Andrew, S. E., and
Tron,V. A. (2010). Inhibition of p38
MAPK enhances ABT-737-induced
cell death in melanoma cell lines:
novel regulation of PUMA. Pigment
Cell Melanoma Res. 23, 430–440.
Keuling, A. M., Felton, K. E., Parker, A.
A., Akbari, M., Andrew, S. E., and
Tron,V. A. (2009). RNA silencing of
Mcl-1 enhances ABT-737-mediated
apoptosis in melanoma: role for a
caspase-8-dependent pathway. PLoS
ONE 4, e6651. doi:10.1371/jour-
nal.pone.0006651
Khaled, A. R., Reynolds, D. A., Young,
H. A., Thompson, C. B., Muegge,
K., and Durum, S. K. (2001).
Interleukin-3 withdrawal induces
an early increase in mitochondr-
ial membrane potential unrelated
to the Bcl-2 family. Roles of intra-
cellular pH, ADP transport, and
F(0)F(1)-ATPase. J. Biol. Chem. 276,
6453–6462.
Frontiers in Oncology | Molecular and Cellular Oncology October 2011 | Volume 1 | Article 34 | 12Anvekar et al. The BCL -2 family and melanoma
Khodadoust, M. S., Verhaegen, M.,
Kappes, F., Riveiro-Falkenbach, E.,
Cigudosa, J. C., Kim, D. S., Chin-
naiyan,A. M.,Markovitz,D. M.,and
Soengas, M. S. (2009). Melanoma
proliferation and chemoresistance
controlled by the DEK oncogene.
Cancer Res. 69, 6405–6413.
Kim,H.,Tu,H.C.,Ren,D.,Takeuchi,O.,
Jeffers, J. R., Zambetti, G. P., Hsieh,
J. J., and Cheng, E. H. (2009). Step-
wise activation of BAX and BAK
by tBID, BIM, and PUMA initiates
mitochondrial apoptosis. Mol. Cell
36, 487–499.
Kim, M. (2010). Cooperative interac-
tions of PTEN deﬁciency and RAS
activation in melanoma metastasis.
Small Gtpases 1, 161–164.
Kluger,H.M.,McCarthy,M.M.,Alvero,
A. B.,Sznol,M.,Ariyan,S.,Camp,R.
L.,Rimm,D. L.,and Mor,G. (2007).
The X-linked inhibitor of apopto-
sis protein (XIAP) is up-regulated
in metastatic melanoma, and XIAP
cleavage by phenoxodiol is associ-
ated with carboplatin sensitization.
J. Transl. Med. 5, 6.
Kobayashi, Y., Ohtsuki, M., Murakami,
T., Kobayashi, T., Sutheesophon,
K., Kitayama, H., Kano, Y., Kusano,
E., Nakagawa, H., and Furukawa,
Y. (2006). Histone deacetylase
inhibitor FK228 suppresses the
Ras-MAP kinase signaling pathway
by upregulating Rap1 and induces
apoptosis in malignant melanoma.
Oncogene 25, 512–524.
Kondo, Y., Kanzawa, T., Sawaya, R.,
and Kondo, S. (2005). The role of
autophagy in cancer development
and response to therapy. Nat. Rev.
Cancer 5, 726–734.
Konopleva, M., Watt, J., Contractor, R.,
Tsao, T., Harris, D., Estrov, Z., Born-
mann, W., Kantarjian, H., Viallet,
J., Samudio, I., and Andreeff, M.
(2008).Mechanismsofantileukemic
activity of the novel Bcl-2 homology
domain-3 mimetic GX15-070 (oba-
toclax). Cancer Res. 68, 3413–3420.
Korabiowska, M., Brinck, U., Ruschen-
burg, I., Schlott, T., Droese, M., and
Stachura, J. (1999). Bcl2 and Bax
expression in naevi and melanomas
and their relation to ploidy status
and proliferation. Pol. J. Pathol. 50,
17–21.
Kuwana, T., Bouchier-Hayes, L.,
Chipuk, J. E., Bonzon, C., Sullivan,
B. A., Green, D. R., and Newmeyer,
D. D. (2005). BH3 domains of
BH3-only proteins differentially
regulate Bax-mediated mitochon-
drial membrane permeabilization
both directly and indirectly. Mol.
Cell 17, 525–535.
Kuwana, T., Mackey, M. R., Perkins,
G., Ellisman, M. H., Latterich,
M., Schneiter, R., Green, D. R.,
and Newmeyer, D. D. (2002).
Bid, Bax, and lipids cooperate to
form supramolecular openings in
the outer mitochondrial membrane.
Cell 111, 331–342.
Lattanzi, S. C., Tosteson, T., Chertoff, J.,
Maurer,L. H.,O’Donnell,J.,LeMar-
bre, P. J., Mott, L., DelPrete, S. A.,
Forcier, R. J., and Ernstoff, M. S.
(1995). Dacarbazine, cisplatin and
carmustine, with or without tamox-
ifen, for metastatic melanoma: 5-
year follow-up. Melanoma Res. 5,
365–369.
Legha, S. S., Ring, S., Bedikian, A.,
Plager, C., Eton, O., Buzaid, A. C.,
andPapadopoulos,N.(1996).Treat-
ment of metastatic melanoma with
combined chemotherapy contain-
ing cisplatin, vinblastine and dacar-
bazine (CVD) and biotherapy using
interleukin-2 and interferon-alpha.
Ann. Oncol. 7, 827–835.
Legha, S. S., Ring, S., Papadopoulos,
N., Plager, C., Chawla, S., and Ben-
jamin,R.(1989).Aprospectiveeval-
uationof atriple-drugregimencon-
taining cisplatin, vinblastine, and
dacarbazine (CVD) for metastatic
melanoma. Cancer 64, 2024–2029.
Leiter, U., Schmid, R. M., Kaskel, P.,
Peter, R. U., and Krahn, G. (2000).
Antiapoptotic bcl-2 and bcl-xL
in advanced malignant melanoma.
Arch. Dermatol. Res. 292, 225–232.
Letai, A., Bassik, M. C., Walensky, L.
D., Sorcinelli, M. D., Weiler, S., and
Korsmeyer,S.J.(2002).DistinctBH3
domains either sensitize or activate
mitochondrial apoptosis, serving as
prototype cancer therapeutics. Can-
cer Cell 2, 183–192.
Letai, A. G. (2008). Diagnosing and
exploiting cancer’s addiction to
blocksinapoptosis.Nat.Rev.Cancer
8, 121–132.
Levine, B., Sinha, S., and Kroemer,
G. (2008). Bcl-2 family members:
dual regulators of apoptosis and
autophagy. Autophagy 4, 600–606.
Li,P.,Nijhawan,D.,Budihardjo,I.,Srini-
vasula,S.M.,Ahmad,M.,Alnemri,E.
S.,andWang,X.(1997).Cytochrome
canddATP-dependentformationof
Apaf-1/caspase-9 complex initiates
an apoptotic protease cascade. Cell
91, 479–489.
Lillehammer, T., Engesaeter, B. O.,
Prasmickaite, L., Maelandsmo, G.
M., Fodstad, O., and Engebraaten,
O. (2007). Combined treatment
with Ad-hTRAIL and DTIC or
SAHA is associated with increased
mitochondrial-mediated apoptosis
in human melanoma cell lines. J.
Gene Med. 9, 440–451.
Lindsten, T., Ross, A. J., King, A., Zong,
W. X., Rathmell, J. C., Shiels, H. A.,
Ulrich, E., Waymire, K. G., Mahar,
P., Frauwirth, K., Chen, Y., Wei, M.,
Eng, V. M., Adelman, D. M., Simon,
M.C.,Ma,A.,Golden,J.A.,Evan,G.,
Korsmeyer, S. J., MacGregor, G. R.,
and Thompson, C. B. (2000). The
combinedfunctionsof proapoptotic
Bcl-2 family members bak and bax
are essential for normal develop-
ment of multiple tissues. Mol. Cell
6, 1389–1399.
Liu, X., Kim, C. N., Yang, J., Jem-
merson, R., and Wang, X. (1996).
Induction of apoptotic program in
cell-free extracts: requirement for
dATP and cytochrome c. Cell 86,
147–157.
Lock,R.,Roy,S.,Keniﬁc,C. M.,Su,J. S.,
Salas,E.,Ronen,S.M.,andDebnath,
J. (2011). Autophagy facilitates gly-
colysis during Ras-mediated onco-
genic transformation. Mol. Biol. Cell
22, 165–178.
Loggini, B., Rinaldi, I., Pingitore,
R., Cristofani, R., Castagna, M.,
and Barachini, P. (2001). Immuno-
histochemical study of 49 cuta-
neousmelanomas:p53,PCNA,Bcl-2
expressionandmultidrugresistance.
Tumori 87, 179–186.
Logue, S. E., and Martin, S. J. (2008).
Caspaseactivationcascadesinapop-
tosis. Biochem. Soc. Trans. 36, 1–9.
Lovell, J. F., Billen, L. P., Bindner, S.,
Shamas-Din,A.,Fradin,C.,Leber,B.,
and Andrews, D. W. (2008). Mem-
brane binding by tBid initiates an
ordered series of events culminat-
ing in membrane permeabilization
by Bax. Cell 135, 1074–1084.
Maddodi,N.,Huang,W.,Havighurst,T.,
Kim, K., Longley, B. J., and Setaluri,
V. (2010). Induction of autophagy
and inhibition of melanoma growth
in vitro and in vivo by hyperacti-
vation of oncogenic BRAF. J. Invest.
Dermatol. 130, 1657–1667.
Malik, S. A., Orhon, I., Morselli, E.,
Criollo, A., Shen, S., Marino, G.,
Benyounes, A., Benit, P., Rustin,
P., Maiuri, M. C., and Kroemer,
G. (2011a). BH3 mimetics activate
multiple pro-autophagic pathways.
Oncogene 30, 3918–3929.
Malik, S. A., Shen, S., Marino, G.,
BenYounes, A., Maiuri, M. C., and
Kroemer, G. (2011b). BH3 mimet-
ics reveal the network properties of
autophagy-regulatory signaling cas-
cades. Autophagy 7, 914–916.
McGill, G. G., Horstmann, M., Wid-
lund, H. R., Du, J., Motyckova,
G., Nishimura, E. K., Lin, Y. L.,
Ramaswamy, S., Avery, W., Ding,
H. F., Jordan, S. A., Jackson, I. J.,
Korsmeyer, S. J., Golub, T. R., and
Fisher, D E. (2002). Bcl2 regulation
by the melanocyte master regulator
Mitf modulates lineage survival and
melanoma cell viability. Cell 109,
707–718.
Melero, I., Hervas-Stubbs, S., Glennie,
M., Pardoll, D. M., and Chen, L.
(2007). Immunostimulatory mono-
clonal antibodies for cancer therapy.
Nat. Rev. Cancer 7, 95–106.
Miller,L.A.,Goldstein,N. B.,Johannes,
W. U., Walton, C. H., Fujita, M.,
Norris, D. A., and Shellman, Y. G.
(2009). BH3 mimetic ABT-737 and
a proteasome inhibitor synergisti-
cally kill melanomas through Noxa-
dependent apoptosis. J. Invest. Der-
matol. 129, 964–971.
Miracco, C., Santopietro, R., Biagioli,
M., Lazzi, S., Nyongo, A., Vatti,
R., and Luzi, P. (1998). Different
patterns of cell proliferation and
death and oncogene expression in
cutaneous malignant melanoma. J.
Cutan. Pathol. 25, 244–251.
Morales-Ducret, C. R., van de Rijn,
M., and Smoller, B. R. (1995). bcl-
2 expression in melanocytic nevi.
Insights into the biology of dermal
maturation. Arch. Dermatol. 131,
915–918.
Munshi, A., Tanaka, T., Hobbs, M. L.,
Tucker, S. L., Richon, V. M., and
Meyn,R.E.(2006).Vorinostat,ahis-
tone deacetylase inhibitor, enhances
theresponseofhumantumorcellsto
ionizing radiation through prolon-
gation of gamma-H2AX foci. Mol.
Cancer Ther. 5, 1967–1974.
Newmeyer, D. D., Farschon, D. M., and
Reed, J. C. (1994). Cell-free apopto-
sis in Xenopus egg extracts: inhibi-
tion by Bcl-2 and requirement for
an organelle fraction enriched in
mitochondria. Cell 79, 353–364.
Nguyen,M.,Marcellus,R. C.,Roulston,
A., Watson, M., Serfass, L., Murthy
Madiraju, S. R., Goulet, D., Vial-
let, J., Belec, L., Billot, X., Acoca, S.,
Purisima, E., Wiegmans, A., Cluse,
L.,Johnstone,R.W.,Beauparlant,P.,
and Shore, G. C. (2007). Small mol-
eculeobatoclax(GX15-070)antago-
nizes MCL-1 and overcomes MCL-
1-mediated resistance to apoptosis.
Proc. Natl. Acad. Sci. U.S.A. 104,
19512–19517.
Nikiforov, M. A., Riblett, M., Tang,
W. H., Gratchouck, V., Zhuang,
D., Fernandez, Y., Verhaegen, M.,
Varambally, S., Chinnaiyan, A. M.,
Jakubowiak,A.J.,andSoengas,M.S.
(2007). Tumor cell-selective regula-
tionof NOXAbyc-MYCinresponse
toproteasomeinhibition.Proc.Natl.
Acad. Sci. U.S.A. 104, 19488–19493.
O’Day, S. J., Hamid, O., and Urba,
W. J. (2007). Targeting cytotoxic T-
lymphocyte antigen-4 (CTLA-4): a
novel strategy for the treatment of
melanoma and other malignancies.
Cancer 110, 2614–2627.
www.frontiersin.org October 2011 | Volume 1 | Article 34 | 13Anvekar et al. The BCL -2 family and melanoma
Ohtsuka, T., Ryu, H., Minamishima, Y.
A., Macip, S., Sagara, J., Nakayama,
K. I.,Aaronson, S. A., and Lee, S. W.
(2004). ASC is a Bax adaptor and
regulates the p53-Bax mitochondr-
ial apoptosis pathway. Nat. Cell Biol.
6, 121–128.
Oltersdorf, T., Elmore, S. W., Shoe-
maker, A. R., Armstrong, R. C.,
Augeri, D. J., Belli, B. A., Bruncko,
M.,Deckwerth,T. L.,Dinges,J.,Haj-
duk, P. J., Joseph, M. K., Kitada, S.,
Korsmeyer,S. J.,Kunzer,A. R.,Letai,
A., Li, C., Mitten, M. J., Nettesheim,
D. G., Ng, S., Nimmer, P. M.,
O’Connor, J. M., Oleksijew, A., Pet-
ros,A.M.,Reed,J.C.,Shen,W.,Tahir,
S. K., Thompson, C. B., Tomaselli,
K.J.,Wang,B.,Wendt,M.D.,Zhang,
H.,Fesik,S.W.,andRosenberg,S.H.
(2005). An inhibitor of Bcl-2 family
proteins induces regression of solid
tumours. Nature 435, 677–681.
Pagliari, L. J., Kuwana, T., Bonzon, C.,
Newmeyer, D. D., Tu, S., Beere, H.
M., and Green, D. R. (2005). The
multidomain proapoptotic mole-
cules Bax and Bak are directly acti-
vated by heat. Proc. Natl. Acad. Sci.
U.S.A. 102, 17975–17980.
Paraiso,K. H.,Xiang,Y.,Rebecca,V. W.,
Abel, E. V., Chen, Y. A., Munko, A.
C., Wood, E., Fedorenko, I. V., Son-
dak, V. K., Anderson, A. R., Ribas,
A., Palma, M. D., Nathanson, K. L.,
Koomen, J. M., Messina, J. L., and
Smalley, K. S. (2011). PTEN loss
confers BRAF inhibitor resistance to
melanoma cells through the sup-
pression of BIM expression. Cancer
Res. 71, 2750–2760.
Patel, P. M., Suciu, S., Mortier, L., Kruit,
W. H., Robert, C., Schadendorf, D.,
Trefzer, U., Punt, C. J., Dummer,
R., Davidson, N., Becker, J., Conry,
R., Thompson, J. A., Hwu, W. J.,
Engelen, K., Agarwala, S. S., Keil-
holz, U., Eggermont, A. M., Spatz,
A., and EORTC Melanoma Group.
(2011).Extendedschedule,escalated
dose temozolomide versus dacar-
bazine in stage IV melanoma: ﬁnal
results of a randomised phase III
study(EORTC18032).Eur.J.Cancer
47, 1476–1483.
Peltonen, K., Kiviharju, T. M., Jarvinen,
P. M., Ra, R., and Laiho, M. (2005).
Melanoma cell lines are suscepti-
ble to histone deacetylase inhibitor
TSA provoked cell cycle arrest and
apoptosis. Pigment Cell Res. 18,
196–202.
Petros, A. M., Olejniczak, E. T., and
Fesik, S. W. (2004). Structural biol-
ogy of the Bcl-2 family of proteins.
Biochim. Biophys. Acta 1644, 83–94.
Phan, G. Q., Attia, P., Steinberg, S.
M., White, D. E., and Rosenberg, S.
A. (2001). Factors associated with
response to high-dose interleukin-
2 in patients with metastatic
melanoma. J. Clin. Oncol. 19,
3477–3482.
Placzek,W.J.,Wei,J.,Kitada,S.,Zhai,D.,
Reed,J.C.,andPellecchia,M.(2010).
A survey of the anti-apoptotic Bcl-
2 subfamily expression in cancer
types provides a platform to predict
the efﬁcacy of Bcl-2 antagonists in
cancertherapy.CellDeathDis.1,e40.
Plettenberg,A., Ballaun, C., Pammer, J.,
Mildner, M., Strunk, D., Weninger,
W., and Tschachler, E. (1995).
Humanmelanocytesandmelanoma
cells constitutively express the Bcl-
2 proto-oncogene in situ and in cell
culture. Am. J. Pathol. 146, 651–659.
Pollock,P. M.,and Meltzer,P. S. (2002).
A genome-based strategy uncov-
ers frequent BRAF mutations in
melanoma. Cancer Cell 2, 5–7.
Pop, C., and Salvesen, G. S. (2009).
Human caspases: activation, speci-
ﬁcity, and regulation. J. Biol. Chem.
284, 21777–21781.
Pratheeshkumar, P., and Kuttan, G.
(2011a). Vernolide-A, a sesquiter-
pene lactone from Vernonia cinerea,
induces apoptosis in B16F-10
melanoma cells by modulating p53
and caspase-3 gene expressions and
regulating NF-κB-mediated bcl-2
activation. Drug Chem. Toxicol. 34,
261–270.
Pratheeshkumar, P., and Kuttan, G.
(2011b). Effect of vernolide-A, a
sesquiterpene lactone from Ver-
nonia cinerea L., on cell-mediated
immune response in B16F-10
metastatic melanoma-bearing mice.
Immunopharmacol.Immunotoxicol.
33, 533–538.
Pratheeshkumar, P., Raphael, T. J., and
Kuttan, G. (2011). Nomilin inhibits
metastasisviainductionofapoptosis
and regulates the activation of tran-
scription factors and the cytokine
proﬁle in B16F-10 cells. Integr Can-
cer Ther. PMID: 21665879. [Epub
ahead of print].
Qin, J. Z., Xin, H., and Nickoloff,
B. J. (2010). Targeting glutamine
metabolism sensitizes melanoma
cells to TRAIL-induced death.
Biochem. Biophys. Res. Commun.
398, 146–152.
Qin, J. Z., Ziffra, J., Stennett, L., Bod-
ner,B.,Bonish,B. K.,Chaturvedi,V.,
Bennett, F., Pollock, P. M., Trent, J.
M., Hendrix, M. J., Rizzo, P., Miele,
L., and Nickoloff, B. J. (2005). Pro-
teasome inhibitors trigger NOXA-
mediated apoptosis in melanoma
and myeloma cells. Cancer Res. 65,
6282–6293.
Raisova, M., Hossini, A. M., Eberle,
J., Riebeling, C., Wieder, T., Sturm,
I., Daniel, P. T., Orfanos, C. E.,
and Geilen, C. C. (2001). The
Bax/Bcl-2 ratio determines the sus-
ceptibility of human melanoma
cells to CD95/Fas-mediated apop-
tosis. J. Invest. Dermatol. 117,
333–340.
Ramsay, J. A., From, L., and Kahn, H.
J.(1995).bcl-2proteinexpressionin
melanocytic neoplasms of the skin.
Mod. Pathol. 8, 150–154.
Reifenberger, J., Knobbe, C. B.,
Sterzinger, A. A., Blaschke, B.,
Schulte, K. W., Ruzicka, T., and
Reifenberger, G. (2004). Frequent
alterations of Ras signaling path-
way genes in sporadic malignant
melanomas. Int. J. Cancer 109,
377–384.
Robert, C., and Ghiringhelli, F. (2009).
What is the role of cytotoxic T
lymphocyte-associated antigen 4
blockade in patients with metasta-
tic melanoma? Oncologist 14,
848–861.
Robert, C., Thomas, L., Bondarenko,
I., O’Day, S., M, D. J., Garbe, C.,
Lebbe, C., Baurain, J. F., Testori, A.,
Grob, J. J., Davidson, N., Richards,
J., Maio, M., Hauschild, A., Miller,
W. H. Jr., Gascon, P., Lotem, M.,
Harmankaya, K., Ibrahim, R., Fran-
cis, S., Chen, T. T., Humphrey, R.,
Hoos,A.,and Wolchok,J. D. (2011).
Ipilimumab plus dacarbazine for
previously untreated metastatic
melanoma. N .E n g l .J .M e d .364,
2517–2526.
Ryan, J. A., Brunelle, J. K., and Letai,
A. (2010). Heightened mitochondr-
ial priming is the basis for apoptotic
hypersensitivityofCD4+CD8+thy-
mocytes.Proc.Natl.Acad.Sci.U.S.A.
107, 12895–12900.
Saenz-Santamaria, M. C., Reed, J.
A., McNutt, N. S., and Shea, C.
R. (1994). Immunohistochemical
expression of BCL-2 in melanomas
and intradermal nevi. J. Cutan.
Pathol. 21, 393–397.
Seeger, J. M., Schmidt, P., Brinkmann,
K., Hombach, A. A., Coutelle, O.,
Zigrino, P., Wagner-Stippich, D.,
Mauch, C., Abken, H., Kronke, M.,
and Kashkar, H. (2010). The pro-
teasome inhibitor bortezomib sensi-
tizes melanoma cells toward adop-
tive CTL attack. Cancer Res. 70,
1825–1834.
Seigler, H. F., Lucas, V. S. Jr., Pickett,
N. J., and Huang, A. T. (1980).
DTIC, CCNU, bleomycin and
vincristine (BOLD) in metasta-
tic melanoma. Cancer 46,
2346–2348.
Selzer, E., Schlagbauer-Wadl, H.,
Okamoto, I., Pehamberger, H.,
Potter, R., and Jansen, B. (1998).
Expression of Bcl-2 family mem-
bers in human melanocytes, in
melanoma metastases and in
melanoma cell lines. Melanoma Res.
8, 197–203.
Shao, Y., and Aplin, A. E. (2010).
Akt3-mediated resistance to
apoptosis in B-RAF-targeted
melanoma cells. Cancer Res. 70,
6670–6681.
Sheridan, C., Brumatti, G., and Martin,
S. J. (2008). Oncogenic B-RafV600E
inhibits apoptosis and promotes
ERK-dependent inactivation of Bad
and Bim. J. Biol. Chem. 283,
22128–22135.
Shibuya, H., Kato, Y., Saito, M., Isobe,
T., Tsuboi, R., Koga, M., Toyota, H.,
and Mizuguchi, J. (2003). Induc-
tion of apoptosis and/or necrosis
following exposure to antitumour
agentsinamelanomacellline,prob-
ably through modulation of Bcl-2
family proteins. Melanoma Res. 13,
457–464.
Shukla, V. K., Hughes, D. C., Hughes,
L. E., McCormick, F., and Padua, R.
A. (1989). ras mutations in human
melanotic lesions: K-ras activation
is a frequent and early event in
melanoma development. Oncogene
Res. 5, 121–127.
Soengas, M. S., and Lowe, S. W. (2003).
Apoptosis and melanoma chemore-
sistance. Oncogene 22, 3138–3151.
Stahl, J. M., Sharma, A., Cheung,
M., Zimmerman, M., Cheng, J. Q.,
Bosenberg,M.W.,Kester,M.,Sandi-
rasegarane, L., and Robertson, G.
P. (2004). Deregulated Akt3 activ-
ity promotes development of malig-
nant melanoma. Cancer Res. 64,
7002–7010.
Steck, P. A., Pershouse, M. A., Jasser, S.
A., Yung, W. K., Lin, H., Ligon, A.
H., Langford, L. A., Baumgard, M.
L.,Hattier,T.,Davis,T.,Frye,C.,Hu,
R., Swedlund, B., Teng, D. H., and
Tavtigian, S. V. (1997). Identiﬁca-
tion of a candidate tumour suppres-
sor gene, MMAC1, at chromosome
10q23.3 that is mutated in multi-
pleadvancedcancers.Nat.Genet.15,
356–362.
Stein, J. A., and Brownell, I. (2008).
Treatment approaches for advanced
cutaneous melanoma. J. Drugs Der-
matol. 7, 175–179.
Stewart, M. L., Fire, E., Keating, A.
E., and Walensky, L. D. (2010).
The MCL-1 BH3 helix is an exclu-
sive MCL-1 inhibitor and apopto-
sis sensitizer. Nat. Chem. Biol. 6,
595–601.
Sviatoha, V., Rundgren, A., Tani, E.,
Hansson,J.,Kleina,R.,andSkoog,L.
(2002). Expression of CD40, CD44,
bcl-2 antigens and rate of cell prolif-
erationonﬁneneedleaspiratesfrom
metastatic melanoma. Cytopathol-
ogy 13, 11–21.
Frontiers in Oncology | Molecular and Cellular Oncology October 2011 | Volume 1 | Article 34 | 14Anvekar et al. The BCL -2 family and melanoma
Takaoka, A., Adachi, M., Okuda, H.,
Sato, S., Yawata, A., Hinoda, Y.,
Takayama, S., Reed, J. C., and Imai,
K. (1997). Anti-cell death activ-
ity promotes pulmonary metasta-
sis of melanoma cells. Oncogene 14,
2971–2977.
Tan, K. O., Tan, K. M., Chan, S. L.,
Yee, K. S., Bevort, M., Ang, K. C.,
and Yu, V. C. (2001). MAP-1, a
novel proapoptotic protein contain-
ing a BH3-like motif that associates
with Bax through its Bcl-2 homol-
ogy domains. J. Biol. Chem. 276,
2802–2807.
Tang, L., Tron, V. A., Reed, J. C.,
Mah, K. J., Krajewska, M., Li, G.,
Zhou, X., Ho, V. C., and Trotter,
M. J. (1998). Expression of apop-
tosis regulators in cutaneous malig-
nant melanoma. Clin. Cancer Res. 4,
1865–1871.
Tchernev,G.,andOrfanos,C.E.(2007).
Downregulation of cell cycle mod-
ulators p21, p27, p53, Rb and
proapoptotic Bcl-2-related proteins
BaxandBakincutaneousmelanoma
is associated with worse patient
prognosis: preliminary ﬁndings. J.
Cutan. Pathol. 34, 247–256.
Thallinger, C., Wolschek, M. F.,
Wacheck, V., Maierhofer, H., Guns-
berg, P., Polterauer, P., Pehamberger,
H., Monia, B. P., Selzer, E., Wolff,
K., and Jansen, B. (2003). Mcl-1
antisense therapy chemosensitizes
human melanoma in a SCID mouse
xenotransplantation model. J.
Invest. Dermatol. 120, 1081–1086.
Tran,M.A.,Smith,C.D.,Kester,M.,and
Robertson, G. P. (2008). Combin-
ing nanoliposomal ceramide with
sorafenib synergistically inhibits
melanoma and breast cancer cell
survival to decrease tumor devel-
opment. Clin. Cancer Res. 14,
3571–3581.
Tron, V. A., Krajewski, S., Klein-Parker,
H., Li, G., Ho, V. C., and Reed,
J. C. (1995). Immunohistochemi-
cal analysis of Bcl-2 protein regula-
tion in cutaneous melanoma. Am. J.
Pathol. 146, 643–650.
Trudel, S., Li, Z. H., Rauw, J., Tiede-
mann, R. E., Wen, X. Y., and Stew-
art, A. K. (2007). Preclinical studies
of the pan-Bcl inhibitor obatoclax
(GX015-070) in multiple myeloma.
Blood 109, 5430–5438.
Tsao, H., Atkins, M. B., and Sober, A.
J.(2004).Managementof cutaneous
melanoma. N .E n g l .J .M e d .351,
998–1012.
Tsao, H., Zhang, X., Benoit, E., and
Haluska, F. G. (1998). Identiﬁ-
cation of PTEN/MMAC1 alter-
ationsinunculturedmelanomasand
melanoma cell lines. Oncogene 16,
3397–3402.
Tsao, H., Zhang, X., Fowlkes, K.,
and Haluska, F. G. (2000). Rel-
ative reciprocity of NRAS and
PTEN/MMAC1 alterations in cuta-
neous melanoma cell lines. Cancer
Res. 60, 1800–1804.
Utikal, J., Leiter, U., Udart, M., Kaskel,
P., Peter, R. U., and Krahn, G. M.
(2002).Expressionofc-mycandbcl-
2 in primary and advanced cuta-
neous melanoma. Cancer Invest. 20,
914–921.
Vachtenheim, J., Ondrusova, L., and
Borovansky, J. (2010). SWI/SNF
chromatin remodeling complex
is critical for the expression of
microphthalmia-associated tran-
scription factor in melanoma cells.
Biochem. Biophys. Res. Commun.
392, 454–459.
VanBrocklin, M. W., Verhaegen, M.,
Soengas, M. S., and Holmen, S. L.
(2009). Mitogen-activated protein
kinase inhibition induces translo-
cation of Bmf to promote apopto-
sis in melanoma. Cancer Res. 69,
1985–1994.
Verhaegen, M., Bauer, J. A., Martin
de la Vega, C., Wang, G., Wolter,
K. G., Brenner, J. C., Nikolovska-
Coleska, Z., Bengtson, A., Nair, R.,
Elder, J. T., Van Brocklin, M., Carey,
T. E., Bradford, C. R., Wang, S.,
and Soengas, M. S. (2006). A novel
BH3 mimetic reveals a mitogen-
activated protein kinase-dependent
mechanism of melanoma cell death
controlled by p53 and reactive
oxygen species. Cancer Res. 66,
11348–11359.
Vousden, K. H., and Lane, D. P. (2007).
p53 in health and disease. Nat. Rev.
Mol. Cell Biol. 8, 275–283.
Vucic, D., Deshayes, K., Ackerly, H.,
Pisabarro, M. T., Kadkhodayan, S.,
Fairbrother, W. J., and Dixit, V.
M. (2002). SMAC negatively reg-
ulates the anti-apoptotic activity
of melanoma inhibitor of apopto-
sis (ML-IAP). J. Biol. Chem. 277,
12275–12279.
Walensky, L. D., Kung, A. L., Escher,
I., Malia, T. J., Barbuto, S., Wright,
R. D., Wagner, G., Verdine, G. L.,
and Korsmeyer, S. J. (2004). Acti-
vation of apoptosis in vivo by a
hydrocarbon-stapledBH3helix.Sci-
ence 305, 1466–1470.
Walensky, L. D., Pitter, K., Morash,
J., Oh, K. J., Barbuto, S., Fisher,
J., Smith, E., Verdine, G. L., and
Korsmeyer, S. J. (2006). A sta-
pled BID BH3 helix directly binds
and activates BAX. Mol. Cell 24,
199–210.
Wan, P. T., Garnett, M. J., Roe, S. M.,
Lee, S., Niculescu-Duvaz, D., Good,
V. M., Jones, C. M., Marshall, C. J.,
Springer, C. J., Barford, D., Marais,
R., and Cancer Genome Project.
(2004). Mechanism of activation of
the RAF-ERK signaling pathway by
oncogenic mutations of B-RAF. Cell
116, 855–867.
Wang, Y. F., Jiang, C. C., Kiejda, K.
A., Gillespie, S., Zhang, X. D., and
Hersey, P. (2007). Apoptosis induc-
tion in human melanoma cells
by inhibition of MEK is caspase-
independent and mediated by the
Bcl-2 family members PUMA, Bim,
and Mcl-1. Clin. Cancer Res. 13,
4934–4942.
Weber, A., Kirejczyk, Z., Potthoff, S.,
Ploner, C., and Hacker, G. (2009).
Endogenous noxa determines the
strong proapoptotic synergism of
the BH3-mimetic ABT-737 with
chemotherapeutic agents in human
melanoma cells. Transl. Oncol. 2,
73–83.
Wei, M. C., Lindsten, T., Mootha, V.
K., Weiler, S., Gross, A., Ashiya, M.,
Thompson, C. B., and Korsmeyer,
S. J. (2000). tBID, a membrane-
targeted death ligand, oligomerizes
BAK to release cytochrome c. Genes
Dev. 14, 2060–2071.
Wei, M. C., Zong, W. X., Cheng, E. H.,
Lindsten, T., Panoutsakopoulou, V.,
Ross, A. J., Roth, K. A., MacGre-
gor, G. R., Thompson, C. B., and
Korsmeyer, S. J. (2001). Proapop-
totic BAX and BAK: a requi-
site gateway to mitochondrial dys-
function and death. Science 292,
727–730.
Willis, S. N., Chen, L., Dewson, G.,
Wei, A., Naik, E., Fletcher, J. I.,
Adams, J. M., and Huang, D.
C. (2005). Proapoptotic Bak is
sequestered by Mcl-1 and Bcl-xL,
but not Bcl-2, until displaced by
BH3-only proteins. Genes Dev. 19,
1294–1305.
Willis, S. N., Fletcher, J. I., Kaufmann,
T.,van Delft,M. F.,Chen,L.,Czabo-
tar,P. E.,Ierino,H.,Lee,E. F.,Fairlie,
W.D.,Bouillet,P.,Strasser,A.,Kluck,
R. M., Adams, J. M., and Huang, D.
C. (2007). Apoptosis initiated when
BH3 ligands engage multiple Bcl-2
homologs, not Bax or Bak. Science
315, 856–859.
Wong, R. P., Khosravi, S., Martinka, M.,
andLi,G.(2008).Myeloidleukemia-
1 expression in benign and malig-
nant melanocytic lesions. Oncol.
Rep. 19, 933–937.
Xie, K.,Wang,Y., Huang, S., Xu, L., Bie-
lenberg, D., Salas, T., McConkey, D.
J., Jiang, W., and Fidler, I. J. (1997).
Nitric oxide-mediated apoptosis of
K-1735 melanoma cells is associ-
ated with downregulation of Bcl-2.
Oncogene 15, 771–779.
Xu, X., Liu, Y., Wang, L., He, J.,
Zhang, H., Chen, X., Li, Y., Yang,
J., and Tao, J. (2009). Gambogic
acid induces apoptosis by regulat-
ing the expression of Bax and Bcl-
2 and enhancing caspase-3 activ-
ity in human malignant melanoma
A375 cells. Int. J. Dermatol. 48,
186–192.
Yamamura, K., Kamada, S., Ito, S., Nak-
agawa, K., Ichihashi, M., and Tsu-
jimoto, Y. (1996). Accelerated dis-
appearance of melanocytes in bcl-
2-deﬁcient mice. Cancer Res. 56,
3546–3550.
Yecies, D., Carlson, N. E., Deng, J.,
and Letai,A. (2010). Acquired resis-
tance toABT-737 in lymphoma cells
that up-regulate MCL-1 and BFL-1.
Blood 115, 3304–3313.
You, M., Savaraj, N., Wangpaichitr,
M., Wu, C., Kuo, M. T., Varona-
Santos, J., Nguyen, D. M., and
Feun,L.(2010).Thecombinationof
ADI-PEG20 and TRAIL effectively
increasescelldeathinmelanomacell
lines. Biochem. Biophys. Res. Com-
mun. 394, 760–766.
Yu, F., Watts, R. N., Zhang, X. D.,
Borrow, J. M., and Hersey, P.
(2006). Involvement of BH3-
only proapoptotic proteins
in mitochondrial-dependent
phenoxodiol-induced apoptosis of
human melanoma cells. Anticancer
Drugs 17, 1151–1161.
Yu, K. S., Lee, Y., Kim, C. M., Park,
E. C., Choi, J., Lim, D. S., Chung,
Y. H., and Koh, S. S. (2010). The
protease inhibitor, elaﬁn, induces
p53-dependent apoptosis in human
melanoma cells. Int. J. Cancer 127,
1308–1320.
Zhang, H., and Rosdahl, I. (2006).
Bcl-xL and bcl-2 proteins in
melanoma progression and UVB-
induced apoptosis. Int. J. Oncol. 28,
661–666.
Zhou, C., Mao, X. P., Guo, Q.,
and Zeng, F. Q. (2009). Dial-
lyl trisulphide-induced apoptosis in
human melanoma cells involves
downregulation of Bcl-2 and Bcl-
xL expression and activation of cas-
pases.Clin.Exp.Dermatol.34,e537–
e543.
Zhou,X.P.,Gimm,O.,Hampel,H.,Nie-
mann, T., Walker, M. J., and Eng,
C. (2000). Epigenetic PTEN silenc-
ing in malignant melanomas with-
out PTEN mutation. Am. J. Pathol.
157, 1123–1128.
Zhuang, L., Scolyer, R. A., Murali,
R., McCarthy, S. W., Zhang, X.
D., Thompson, J. F., and Hersey,
P. (2010). Lactate dehydrogenase 5
expression in melanoma increases
withdiseaseprogressionandisasso-
ciatedwithexpressionof Bcl-XLand
Mcl-1, but not Bcl-2 proteins. Mod.
Pathol. 23, 45–53.
www.frontiersin.org October 2011 | Volume 1 | Article 34 | 15Anvekar et al. The BCL -2 family and melanoma
Zobel, K., Wang, L., Varfolomeev, E.,
Franklin, M. C., Elliott, L. O., Wall-
weber,H. J.,Okawa,D. C.,Flygare,J.
A., Vucic, D., Fairbrother, W. J., and
Deshayes,K.(2006).Design,synthe-
sis,andbiologicalactivityofapotent
Smac mimetic that sensitizes can-
cercellstoapoptosisbyantagonizing
IAPs. ACS Chem. Biol. 1, 525–533.
Zou, H., Henzel, W. J., Liu, X., Lutschg,
A., and Wang, X. (1997). Apaf-1,
a human protein homologous to
C. elegans CED-4, participates in
cytochrome c-dependent activation
of caspase-3. Cell 90, 405–413.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 05 August 2011; accepted: 22
September 2011; published online: 13
October 2011.
Citation: Anvekar RA, Asciolla JJ, Mis-
sert DJ and Chipuk JE (2011) Born to
be alive: a role for the BCL-2 family in
melanoma tumor cell survival, apoptosis,
and treatment. Front. Oncol. 1:34. doi:
10.3389/fonc.2011.00034
This article was submitted to Frontiers
in Molecular and Cellular Oncology, a
specialty of Frontiers in Oncology.
Copyright © 2011 Anvekar, Asciolla,
Missert and Chipuk. This is an open-
access article subject to a nonexclu-
sive license between the authors and
Frontiers Media SA, which permits
use, distribution and reproduction in
other forums, provided the original
authors and source are credited and
other Frontiers conditions are complied
with.
Frontiers in Oncology | Molecular and Cellular Oncology October 2011 | Volume 1 | Article 34 | 16